Leitlinienprogramm OnkologieCervical Carcinoma

30. Literaturverzeichnis – Cervical Carcinoma

Version 2.2 · March 2022 · AWMF 032/033OL
Leitlinienprogramm Onkologie · Deutsche Krebsgesellschaft · Deutsche Krebshilfe · AWMF

1. AWMF, Diagnostik und Therapie des Zervixkarzinoms, 2008.

2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Staendige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:, http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html

4. Seifert, U., Klug, S. J., Early detection of cervical cancer in Germany : Evidence and implementation, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2014. 57: p. 294-301., https://www.ncbi.nlm.nih.gov/pubmed/24562703

6. Brotherton, J. M., Fridman, M., May, C. L., Chappell, G., Saville, A. M., Gertig, D. M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study, Lancet, 2011. 377(9783): p. 2085-92.

7. Luostarinen, T., Apter, D., Dillner, J., Eriksson, T., Harjula, K., Natunen, K., et.al. Vaccination protects against invasive HPV-associated cancers, Int J Cancer, 2018. 142(10): p. 2186-2187., https://www.ncbi.nlm.nih.gov/pubmed/29280138

8. Drolet, M., Benard, E., Boily, M. C., Ali, H., Baandrup, L., Bauer, H., et.al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis, Lancet Infect Dis, 2015. 15(5): p. 565-80., https://www.ncbi.nlm.nih.gov/pubmed/25744474

9. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID), 2014. 2014:, https://www.gekid.de/

10. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID), 2014. 2019:, https://atlas.gekid.de/CurrentVersion/atlas.html

11. Marquardt, Katrin, Kossowski, Izabella, Hantschke-Zerbich, Heike, Michel, Frank, An der Schwelle zum organisierten Zervixkarzinomscreening, Der Gynäkologe, 2019. 52(8): p. 622-627.

12. Kainz, C., Tempfer, C., Gitsch, G., Heinzl, H., Reinthaller, A., Breitenecker, G., Influence of age and human papillomavirus-infection on reliability of cervical cytopathology, Arch Gynecol Obstet, 1995. 256(1): p. 23-8., http://www.ncbi.nlm.nih.gov/pubmed/7726650, http://link.springer.com/content/pdf/10.1007%2FBF00634344.pdf

13. Blohmer, J. U., Schmalisch, G., Klette, I., Grineisen, Y., Kohls, A., Guski, H., et.al. Increased incidence of cervical intraepithelial neoplasia in young women in the Mitte district, Berlin, Germany, Acta Cytol, 1999. 43(2): p. 195-200., http://www.ncbi.nlm.nih.gov/pubmed/10097709, http://www.karger.com/Article/Pdf/330976

15. Arbeitsgemeinschaft Deutscher Tumorzentren e.V.; 7. Bundesweite Onkologische Qualitätskonferenz 2018 Zervixkarzinom (Available from: http://www.tumorzentren.de/tl_files/dokumente/Qualitaetskonferenzen/7.%20Bundesweite%20Qualitaetskonferenz/Zervix_Qualikonferenz_Jackisch.pdf), 2018., https://www.adt-netzwerk.de/?s=839

16. Tattersall, M. H., Lorvidhaya, V., Vootiprux, V., Cheirsilpa, A., Wong, F., Azhar, T., et.al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association, J Clin Oncol, 1995. 13(2): p. 444-51., http://www.ncbi.nlm.nih.gov/pubmed/7844607, http://jco.ascopubs.org/content/13/2/444.full.pdf

17. Bray, F., Carstensen, B., Moller, H., Zappa, M., Zakelj, M. P., Lawrence, G., et.al. Incidence trends of adenocarcinoma of the cervix in 13 European countries, Cancer Epidemiol Biomarkers Prev, 2005. 14(9): p. 2191-9., http://cebp.aacrjournals.org/content/14/9/2191.full.pdf

18. Liu, S., Semenciw, R., Mao, Y., Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women, CMAJ, 2001. 164(8): p. 1151-2., http://www.cmaj.ca/content/164/8/1151.full.pdf

19. Parkin, D. M., Bray, F. I., Devesa, S. S., Cancer burden in the year 2000. The global picture, Eur J Cancer, 2001. 37 Suppl 8: p. S4-66.

20. Sasieni, P., Adams, J., Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England, Lancet, 2001. 357(9267): p. 1490-3., https://pubmed.ncbi.nlm.nih.gov/11377601/

21. Smith, H. O., Tiffany, M. F., Qualls, C. R., Key, C. R., The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study, Gynecol Oncol, 2000. 78(2): p. 97-105., https://pubmed.ncbi.nlm.nih.gov/10926787/

22. Vinh-Hung, V., Bourgain, C., Vlastos, G., Cserni, G., De Ridder, M., Storme, G., et.al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study, BMC Cancer, 2007. 7: p. 164., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994954/pdf/1471-2407-7-164.pdf

23. Visioli, C. B., Zappa, M., Ciatto, S., Iossa, A., Crocetti, E., Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Programme, 1985-2000, Cancer Detect Prev, 2004. 28(6): p. 461-4., https://pubmed.ncbi.nlm.nih.gov/15582270/

24. Vizcaino, A. P., Moreno, V., Bosch, F. X., Munoz, N., Barros-Dios, X. M., Parkin, D. M., International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas, Int J Cancer, 1998. 75(4): p. 536-45., https://pubmed.ncbi.nlm.nih.gov/9466653/

26. Appleby, P., Beral, V., Berrington de Gonzalez, A., Colin, D., Franceschi, S., Goodhill, A., et.al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies, Lancet, 2007. 370: p. 1609-21., https://pubmed.ncbi.nlm.nih.gov/17993361/

27. Franceschi, S., The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer, Recent Results Cancer Res, 2005. 166: p. 277-97.

28. IARC, Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, IARC Monogr Eval Carcinog Risks Hum, 2007. 91: p. 1-528.

29. Moreno, V., Bosch, F. X., Munoz, N., Meijer, C. J., Shah, K. V., Walboomers, J. M., et.al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study, Lancet, 2002. 359: p. 1085-92.

30. Castellsague, X., Bosch, F. X., Munoz, N., Environmental co-factors in HPV carcinogenesis, Virus Res, 2002. 89: p. 191-9.

31. Wang, S. S., Bratti, M. C., Rodriguez, A. C., Herrero, R., Burk, R. D., Porras, C., et.al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer, J Infect Dis, 2009. 199: p. 20-30.

32. Wang, S. S., Gonzalez, P., Yu, K., Porras, C., Li, Q., Safaeian, M., et.al. Common genetic variants and risk for HPV persistence and progression to cervical cancer, PLoS One, 2010. 5: p. e8667.

33. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et.al. Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 2003. 348: p. 518-27.

34. Plummer, M., Herrero, R., Franceschi, S., Meijer, C. J., Snijders, P., Bosch, F. X., et.al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study, Cancer Causes Control, 2003. 14: p. 805-14.

35. Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., Castle, P. E., Human papillomavirus testing in the prevention of cervical cancer, J Natl Cancer Inst, 2011. 103(5): p. 368-83., http://www.ncbi.nlm.nih.gov/pubmed/21282563

36. Roura, E., Travier, N., Waterboer, T., de Sanjose, S., Bosch, F. X., Pawlita, M., et.al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort, PLoS One, 2016. 11(1): p. e0147029., https://www.ncbi.nlm.nih.gov/pubmed/26808155

37. Cortessis, V. K., Barrett, M., Brown Wade, N., Enebish, T., Perrigo, J. L., Tobin, J., et.al. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis, Obstet Gynecol, 2017. 130(6): p. 1226-1236., https://www.ncbi.nlm.nih.gov/pubmed/29112647

38. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et.al. Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 2003. 348: p. 518-27., https://www.ncbi.nlm.nih.gov/pubmed/12571259

39. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., et.al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol, 1999. 189: p. 12-19., https://www.ncbi.nlm.nih.gov/pubmed/10451482

40. Klug, S. J., Hukelmann, M., Hollwitz, B., Duzenli, N., Schopp, B., Petry, K. U., et.al. Prevalence of human papillomavirus types in women screened by cytology in Germany, J Med Virol, 2007. 79: p. 616-25., https://www.ncbi.nlm.nih.gov/pubmed/17385693

41. Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., et.al. Condom use and the risk of genital human papillomavirus infection in young women, N Engl J Med, 2006. 354: p. 2645-54., https://www.ncbi.nlm.nih.gov/pubmed/16790697

42. Castellsague, X., Bosch, F. X., Munoz, N., Environmental co-factors in HPV carcinogenesis, Virus Res, 2002. 89: p. 191-9., https://www.ncbi.nlm.nih.gov/pubmed/12445659

43. Frazer, I. H., Leggatt, G. R., Mattarollo, S. R., Prevention and treatment of papillomavirus-related cancers through immunization, Annu Rev Immunol, 2011. 29: p. 111-38., https://www.ncbi.nlm.nih.gov/pubmed/21166538

44. Bray, F., Carstensen, B., Moller, H., Zappa, M., Zakelj, M. P., Lawrence, G., et.al. Incidence trends of adenocarcinoma of the cervix in 13 European countries, Cancer Epidemiol Biomarkers Prev, 2005. 14: p. 2191-9., https://www.ncbi.nlm.nih.gov/pubmed/16172231

45. Hillemanns, Peter, HPV-Impfstoff der Zweiten Generation: Gegen neun Virustypen gerichtet, Dtsch Arztebl International, 2013. 110(51-52): p. 2479-80., https://www.aerzteblatt.de/int/article.asp?id=152479

46. Joura, E. A., Giuliano, A. R., Iversen, O. E., Bouchard, C., Mao, C., Mehlsen, J., et.al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women, N Engl J Med, 2015. 372(8): p. 711-23., https://www.ncbi.nlm.nih.gov/pubmed/25693011

47. Ständige Impfkommission (STIKO) am RKI, Epidemiologisches Bulletin Nr. 35/2014Robert Koch-Institut, 2014., https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/35_14.pdf

48. Ständige Impfkommission (STIKO) am RKI, Epidemiologisches Bulletin Nr. 26/2018Robert Koch Institut, 2018., https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/26_18.pdf

50. Geyer, S., Jaunzeme, J., Hillemanns, P., Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data, Arch Gynecol Obstet, 2014. p. 623–629., http://www.ncbi.nlm.nih.gov/pubmed/25138124

51. Gemeinsamer Bundesausschuss, Beschluss über eine Änderung der Beauftragung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen: zur Erstellung von Einladungsschreiben und Versicherteninformation zum ZervixkarzinomscreeningGemeinsamer Bundesausschuss,, 2016., https://www.g-ba.de/downloads/39-261-2713/2016-09-15_Aenderung_Beauftragung-IQWiG_Einladung_Zervixkarzinom-Screening_vom-2015-03-19.pdf

52. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen, 2018., https://www.g-ba.de/downloads/39-261-3597/2018-11-22_oKFE-RL_Zervixkarzinom.pdf

53. Urologie, DGU- Deutsche Gesellschaft für, S3-LL-Prostata-Ca.pdf, 2011.

54. DKG - German Cancer Society, Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau (Leitlinienprogramm Onkologie von AWMF, DKG und DKH), 2012.

55. Gysels, M., Higginson, I. J., Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomised trials, Support Care Cancer, 2007. 15: p. 7-20.

56. Nilsen, E. S., Myrhaug, H. T., Johansen, M., Oliver, S., Oxman, A. D., Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material, Cochrane Database Syst Rev, 2006. p. CD004563.

57. Wofford, J. L., Smith, E. D., Miller, D. P., The multimedia computer for office-based patient education: a systematic review, Patient Educ Couns, 2005. 59: p. 148-57.

58. Horton, John, Principles of biomedical ethics: Fifth edition. T. L. Beauchamp and J. F. Childress. New York: Oxford University Press, 2001. xiv454pp. ISBN 0-19-514332-9, Trans R Soc Trop Med Hyg, 2002. 96: p. 107.

59. Sieber, W. J., Kaplan, R. M., Informed adherence: the need for shared medical decision making, Control Clin Trials, 2000. 21(5 Suppl): p. 233s-40s., https://www.sciencedirect.com/science/article/abs/pii/S0197245600000842

60. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328: p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034

61. Jansen, S. J., Otten, W., Baas-Thijssen, M. C., van de Velde, C. J., Nortier, J. W., Stiggelbout, A. M., Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients, J Clin Oncol, 2005. 23: p. 6623-30., https://www.ncbi.nlm.nih.gov/pubmed/16170169

62. Wagner, K., Koller, M., Keil, A., Trott, D., Engenhart-Cabillic, R., Pfab, R., et.al. Radiotherapy in surgical and nonsurgical patients. Therapy expectations, quality of life and physician assessment, Chirurg, 1998. 69: p. 252-8., https://www.ncbi.nlm.nih.gov/pubmed/9576035

63. Weis, J., Giesler, J. M., Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence, Patient Educ Couns, 2008. 73: p. 511-8., https://www.ncbi.nlm.nih.gov/pubmed/18952394

64. Chouliara, Z., Kearney, N., Stott, D., Molassiotis, A., Miller, M., Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature, Ann Oncol, 2004. 15(11): p. 1596-602., https://pubmed.ncbi.nlm.nih.gov/15520059/

65. Hagerty, R. G., Butow, P. N., Ellis, P. M., Dimitry, S., Tattersall, M. H., Communicating prognosis in cancer care: a systematic review of the literature, Ann Oncol, 2005. 16(7): p. 1005-53., https://pubmed.ncbi.nlm.nih.gov/15939716/

66. Steinbach K., van Oorschot B., Anselm R., Leppert K, Schweitzer S, Hausmann C, et.al. Wer soll entscheiden?, Deutsches Ärzteblatt, 2004. 41: p. A2741.

67. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms - Langversion 4.2 – August 2019 AWMF-Registernummer: 032-045OL, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.3/LL_Mammakarzinom_Langversion_4.3.pdf

68. Leroy, T., Gabelle Flandin, I., Habold, D., Hannoun-Levi, J. M., The impact of radiation therapy on sexual function, Cancer Radiother, 2012. 16: p. 377-85., https://www.ncbi.nlm.nih.gov/pubmed/22921960

69. Berger-Hoger, B., Liethmann, K., Muhlhauser, I., Haastert, B., Steckelberg, A., Informed shared decision-making supported by decision coaches for women with ductal carcinoma in situ: study protocol for a cluster randomized controlled trial, Trials, 2015. 16: p. 452., https://www.ncbi.nlm.nih.gov/pubmed/26458964

70. Rahn, A. C., Kopke, S., Kasper, J., Vettorazzi, E., Muhlhauser, I., Heesen, C., Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial, Trials, 2015. 16: p. 106., https://www.ncbi.nlm.nih.gov/pubmed/25872529

71. Albert, U. S., Schulz, K. D., Alt, D., Beck, V., Doherty, J., Holsteg, K., et.al. A guideline for guidelines-methodological report and use of the guideline women's information, Zentralbl Gynakol, 2003. 125: p. 484-93., https://www.ncbi.nlm.nih.gov/pubmed/14755359

72. O'Connor, A. M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, BMJ, 1999. 319: p. 731-4., https://www.ncbi.nlm.nih.gov/pubmed/10487995

73. Bürgerliches Gesetzbuch §630d Einwilligung, 2020., https://www.buergerliches-gesetzbuch.info/bgb/630d.html

74. NHS, Effective Health Care: Informing, communicating and sharing decision with people who have cancer, NHS Centre for Reviews and Dissemination. Plymouth: Latimer Trend & Company Ltd, 2000.

75. Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., et.al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline, CA Cancer J Clin, 2016. 66(1): p. 43-73., https://www.ncbi.nlm.nih.gov/pubmed/26641959

76. Du, S., Hu, L., Dong, J., Xu, G., Jin, S., Zhang, H., et.al. Patient education programs for cancer-related fatigue: A systematic review, Patient Educ Couns, 2015. 98(11): p. 1308-19., https://www.ncbi.nlm.nih.gov/pubmed/26072422

77. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603., https://www.ncbi.nlm.nih.gov/pubmed/25071125

78. Konsultationsfassung S3 Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen - Langerversion 1.01 - November 2020 AWMF-Registernummer: 032/055OL, 2020., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Komplement%C3%A4r/Version_1/LL_Komplement%C3%A4r_Langversion_1.01.pdf

79. DKG - German Cancer Society, Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau (Leitlinienprogramm Onkologie von AWMF, DKG und DKH), 2012., http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

80. O'Connor, A. M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., et.al. Decision aids for patients facing health treatment or screening decisions: systematic review, BMJ, 1999. 319: p. 731-4.

81. Crockett, R. A., Sutton, S., Walter, F. M., Clinch, M., Marteau, T. M., Benson, J., Impact on decisions to start or continue medicines of providing information to patients about possible benefits and/or harms: a systematic review and meta-analysis, Med Decis Making, 2011. 31: p. 767-77.

82. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines) 1.2014 Cervical Cancer.pdf, 2014.

83. Butow, P. N., Maclean, M., Dunn, S. M., Tattersall, M. H., Boyer, M. J., The dynamics of change: cancer patients preferences for information, involvement and support, Ann Oncol, 1997. 8: p. 857-63., https://www.ncbi.nlm.nih.gov/pubmed/9358935

84. Degner, L. F., Kristjanson, L. J., Bowman, D., Sloan, J. A., Carriere, K. C., O'Neil, J., et.al. Information needs and decisional preferences in women with breast cancer, JAMA, 1997. 277: p. 1485-92., https://www.ncbi.nlm.nih.gov/pubmed/9145723

85. Leinster SJ, Ashcroft JJ, Slade PD, et al., Mastectomy versus conservative surgery: psychosocial effects of the patients choice of treatment, J Psychosoc Oncol, 1989. 7: p. 179-192.

86. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., WHO Classification of Tumours of the Female Genital TractIARC Press, 2014. p. 169-206.

87. Wittekind, C, Meyer, HJ, TNM-Klassifikation maligner TumorenViley-VCH Verlag, 2010.

88. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., WHO Classification of Tumours of the Female Genital TractIARC Press, 2014. p. 169-206.

89. Wittekind, C, Meyer, HJ, TNM-Klassifikation maligner TumorenViley-VCH Verlag, 2010.

90. Wittekind, C, Meyer, HJ, TNM-Klassifikation maligner TumorenViley-VCH Verlag, 2010.

91. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., WHO Classification of Tumours of the Female Genital TractIARC Press, 2014. p. 169-206.

92. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines) 1.2014 Cervical Cancer.pdf, 2014., http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

93. SIGN, Management of cervical cancer - A national clinical guideline, 2008., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174776/

94. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines) 1.2014 Cervical Cancer.pdf, 2014., http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

95. Horn, L. C., Brambs, C. E., Opitz, S., Ulrich, U. A., Hohn, A. K., [The 2019 FIGO classification for cervical carcinoma-what's new?], Pathologe, 2019. 40(6): p. 629-635., https://www.ncbi.nlm.nih.gov/pubmed/31612260

96. Dappa, E., Elger, T., Hasenburg, A., Duber, C., Battista, M. J., Hotker, A. M., The value of advanced MRI techniques in the assessment of cervical cancer: a review, Insights Imaging, 2017. 8(5): p. 471-481., https://www.ncbi.nlm.nih.gov/pubmed/28828723

97. Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., Kim, S. H., Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: An updated systematic review and meta-analysis of the literature between 2012 and 2016, Eur Radiol, 2018. 28(2): p. 530-541., https://www.ncbi.nlm.nih.gov/pubmed/28726120

98. SIGN, SIGN: Management of Cervical Cancer, 2008.

99. Bipat, S., Glas, A. S., van der Velden, J., Zwinderman, A. H., Bossuyt, P. M., Stoker, J., Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review, Gynecol Oncol, 2003. 91(1): p. 59-66.

100. Thomeer, M. G., Gerestein, C., Spronk, S., van Doorn, H. C., van der Ham, E., Hunink, M. G., Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis, Eur Radiol, 2013. 23(7): p. 2005-18., http://download.springer.com/static/pdf/254/art%253A10.1007%252Fs00330-013-2783-4.pdf?auth66=1392375236_9bca73cd15ec7d965b9126f42a2a136c&ext=.pdf

101. SIGN, SIGN: Management of Cervical Cancer, 2008.

102. Bipat, S., Glas, A. S., van der Velden, J., Zwinderman, A. H., Bossuyt, P. M., Stoker, J., Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review, Gynecol Oncol, 2003. 91: p. 59-66., https://www.ncbi.nlm.nih.gov/pubmed/14529663

103. Thomeer, M. G., Gerestein, C., Spronk, S., van Doorn, H. C., van der Ham, E., Hunink, M. G., Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis, Eur Radiol, 2013. 23(7): p. 2005-18., https://www.ncbi.nlm.nih.gov/pubmed/23455762

105. Choi, H. J., Ju, W., Myung, S. K., Kim, Y., Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis (Structured abstract), Cancer Science, 2010. 101: p. 1471-1479., https://www.ncbi.nlm.nih.gov/pubmed/20298252

106. Epstein, E., Testa, A., Gaurilcikas, A., Di Legge, A., Ameye, L., Atstupenaite, V., et.al. Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial, Gynecol Oncol, 2013. 128(3): p. 449-53., https://www.ncbi.nlm.nih.gov/pubmed/23022593

107. Delgado, G., Bundy, B., Zaino, R., Sevin, B. U., Creasman, W. T., Major, F., Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, Gynecol Oncol, 1990. 38: p. 352-7., https://www.ncbi.nlm.nih.gov/pubmed/2227547

108. Lagasse, L. D., Creasman, W. T., Shingleton, H. M., Ford, J. H., Blessing, J. A., Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group, Gynecol Oncol, 1980. 9(1): p. 90-8.

109. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31(24): p. 3026-33., https://www.ncbi.nlm.nih.gov/pubmed/23857967

110. Tsai, C. S., Lai, C. H., Chang, T. C., Yen, T. C., Ng, K. K., Hsueh, S., et.al. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy, Int J Radiat Oncol Biol Phys, 2010. 76: p. 477-84., https://www.ncbi.nlm.nih.gov/pubmed/19464824

111. Kang, S., Kim, S. K., Chung, D. C., Seo, S. S., Kim, J. Y., Nam, B. H., et.al. Diagnostic value of 18F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a meta-analysis (Structured abstract), Journal of Nuclear Medicine, 2010. 51: p. 360-367., https://www.ncbi.nlm.nih.gov/pubmed/20150275

112. De Cuypere, M., Lovinfosse, P., Goffin, F., Gennigens, C., Rovira, R., Duch, J., et.al. Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study, Eur J Surg Oncol, 2020. 46(5): p. 883-887., https://www.ncbi.nlm.nih.gov/pubmed/31784203

113. Martinez, A., Voglimacci, M., Lusque, A., Ducassou, A., Gladieff, L., Dupuis, N., et.al. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer, Eur J Nucl Med Mol Imaging, 2020. 47(5): p. 1252-1260., https://www.ncbi.nlm.nih.gov/pubmed/31915897

114. Liu, B., Gao, S., Li, S., A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67 Studies, Gynecol Obstet Invest, 2017. 82(3): p. 209-222., https://www.ncbi.nlm.nih.gov/pubmed/28183074

115. Kang, S., Kim, S. K., Chung, D. C., Seo, S. S., Kim, J. Y., Nam, B. H., et.al. Diagnostic value of 18F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a meta-analysis (Structured abstract), Journal of Nuclear Medicine, 2010. 51: p. 360-367.

116. Choi, H. J., Ju, W., Myung, S. K., Kim, Y., Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis (Structured abstract), Cancer Science, 2010. 101(6): p. 1471-1479., http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005302/frame.html

117. Tsai, C. S., Lai, C. H., Chang, T. C., Yen, T. C., Ng, K. K., Hsueh, S., et.al. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy, Int J Radiat Oncol Biol Phys, 2010. 76(2): p. 477-84., http://www.ncbi.nlm.nih.gov/pubmed/19464824

118. Kang, S., Kim, S. K., Chung, D. C., Seo, S. S., Kim, J. Y., Nam, B. H., et.al. Diagnostic value of 18F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a meta-analysis (Structured abstract), Journal of Nuclear Medicine, 2010. 51(3): p. 360-367., http://jnm.snmjournals.org/content/51/3/360.full.pdf

119. Choi, H. J., Ju, W., Myung, S. K., Kim, Y., Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis (Structured abstract), Cancer Science, 2010. 101: p. 1471-1479.

120. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31: p. 3026-33.

121. Elit, L. M., Fyles, A. W., Gu, C. S., Pond, G. R., D'Souza, D., Samant, R., et.al. Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial, JAMA Netw Open, 2018. 1(5): p. e182081., https://www.ncbi.nlm.nih.gov/pubmed/30646153

122. Lin, S. Y., Tsai, C. S., Chang, Y. C., Ng, K. K., Chang, T. C., Kao, W. H., et.al. The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up, International journal of radiation oncology, biology, physics, 2015. 92(3): p. 577-85., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/013/CN-01084013/frame.html

123. Small, W., Jr., Winter, K., Levenback, C., Iyer, R., Gaffney, D., Asbell, S., et.al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116, Int J Radiat Oncol Biol Phys, 2007. 68(4): p. 1081-7.

124. Atri, M., Zhang, Z., Dehdashti, F., Lee, S. I., Ali, S., Marques, H., et.al. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial, Gynecol Oncol, 2016. 142(3): p. 413-9., https://www.ncbi.nlm.nih.gov/pubmed/27178725

125. Han, S., Kim, H., Kim, Y. J., Suh, C. H., Woo, S., Prognostic Value of Volume-Based Metabolic Parameters of (18)F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis, AJR Am J Roentgenol, 2018. 211(5): p. 1112-1121., https://www.ncbi.nlm.nih.gov/pubmed/30207790

126. Liu, F. Y., Lai, C. H., Yang, L. Y., Wang, C. C., Lin, G., Chang, C. J., et.al. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial, Eur J Nucl Med Mol Imaging, 2016. 43(10): p. 1812-23., https://www.ncbi.nlm.nih.gov/pubmed/27160224

127. Ding, X. P., Feng, L., Ma, L., Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis, Arch Gynecol Obstet, 2014. 290(4): p. 741-7., https://www.ncbi.nlm.nih.gov/pubmed/24798933

128. Xiao, Y., Wei, J., Zhang, Y., Xiong, W., Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis, Arch Med Sci, 2014. 10(2): p. 222-31., https://www.ncbi.nlm.nih.gov/pubmed/24904653

129. Meads, C., Auguste, P., Davenport, C., Malysiak, S., Sundar, S., Kowalska, M., et.al. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling, Health Technol Assess, 2013. 17(12): p. 1-323., http://www.ncbi.nlm.nih.gov/pubmed/23537558

130. Meads, C., Davenport, C., Malysiak, S., Kowalska, M., Zapalska, A., Guest, P., et.al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation, BJOG, 2014. 121(4): p. 398-407., https://www.ncbi.nlm.nih.gov/pubmed/24299154

131. Brooks, R. A., Rader, J. S., Dehdashti, F., Mutch, D. G., Powell, M. A., Thaker, P. H., et.al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer, Gynecol Oncol, 2009. 112(1): p. 104-9.

132. Schwarz, J. K., Siegel, B. A., Dehdashti, F., Grigsby, P. W., Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma, Jama, 2007. 298(19): p. 2289-95.

133. Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., et.al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document, Ann Oncol, 2010. 21: p. 448-58., https://www.ncbi.nlm.nih.gov/pubmed/20176693

134. Testa, A. C., Di Legge, A., De Blasis, I., Moruzzi, M. C., Bonatti, M., Collarino, A., et.al. Imaging techniques for the evaluation of cervical cancer, Best Pract Res Clin Obstet Gynaecol, 2014. 28(5): p. 741-68., https://www.ncbi.nlm.nih.gov/pubmed/24861248

135. Pinkavova, I., Fischerova, D., Zikan, M., Burgetova, A., Slama, J., Svarovsky, J., et.al. Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer, Ultrasound Obstet Gynecol, 2013. 42(6): p. 705-12., https://www.ncbi.nlm.nih.gov/pubmed/23495185

136. Alcazar, J. L., Arribas, S., Minguez, J. A., Jurado, M., The role of ultrasound in the assessment of uterine cervical cancer, J Obstet Gynaecol India, 2014. 64(5): p. 311-6., https://www.ncbi.nlm.nih.gov/pubmed/25368452

137. Palsdottir, K., Fischerova, D., Franchi, D., Testa, A., Di Legge, A., Epstein, E., Preoperative prediction of lymph node metastasis and deep stromal invasion in women with invasive cervical cancer: prospective multicenter study using 2D and 3D ultrasound, Ultrasound Obstet Gynecol, 2015. 45(4): p. 470-5., https://www.ncbi.nlm.nih.gov/pubmed/25092154

138. Huang, Y. F., Cheng, Y. M., Wu, Y. P., Chen, H. H., Hsu, K. F., Wu, Y. H., et.al. Three-dimensional power Doppler ultrasound in cervical carcinoma: monitoring treatment response to radiotherapy, Ultrasound Obstet Gynecol, 2013. 42(1): p. 84-92., https://www.ncbi.nlm.nih.gov/pubmed/22744872

139. Testa, A. C., Ferrandina, G., Moro, F., Pasciuto, T., Moruzzi, M. C., De Blasis, I., et.al. PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery, Ultrasound Obstet Gynecol, 2018. 51(5): p. 684-695., https://www.ncbi.nlm.nih.gov/pubmed/28620930

140. Byun, J. M., Kim, Y. N., Jeong, D. H., Kim, K. T., Sung, M. S., Lee, K. B., Three-dimensional transvaginal ultrasonography for locally advanced cervical cancer, Int J Gynecol Cancer, 2013. 23(8): p. 1459-64., https://www.ncbi.nlm.nih.gov/pubmed/24257560

141. Bakay, O. A., Golovko, T. S., Use of elastography for cervical cancer diagnostics, Exp Oncol, 2015. 37(2): p. 139-45., https://www.ncbi.nlm.nih.gov/pubmed/26112943

142. WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4), 2020. 2020:, https://publications.iarc.fr/592

143. Adegoke, O., Kulasingam, S., Virnig, B., Cervical cancer trends in the United States: a 35-year population-based analysis, J Womens Health (Larchmt), 2012. 21(10): p. 1031-7.

144. Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., et.al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal, Mod Pathol, 2018. 31(12): p. 1770-1786., https://www.ncbi.nlm.nih.gov/pubmed/30140036

145. Horn, L. C., Hentschel, B., Bilek, K., Richter, C. E., Einenkel, J., Leo, C., Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index, Ann Diagn Pathol, 2006. 10: p. 140-3., https://www.ncbi.nlm.nih.gov/pubmed/16730307

146. Ganesan, R., Hirschowitz, L., Dawson, P., Askew, S., Pearmain, P., Jones, P. W., et.al. Neuroendocrine Carcinoma of the Cervix: Review of a Series of Cases and Correlation With Outcome, Int J Surg Pathol, 2016. 24(6): p. 490-6., https://www.ncbi.nlm.nih.gov/pubmed/27098591

147. Cohen, J. G., Kapp, D. S., Shin, J. Y., Urban, R., Sherman, A. E., Chen, L. M., et.al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients, Am J Obstet Gynecol, 2010. 203: p. 347 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20579961

148. Lee, S. W., Nam, J. H., Kim, D. Y., Kim, J. H., Kim, K. R., Kim, Y. M., et.al. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study, Int J Gynecol Cancer, 2010. 20: p. 411-6., https://www.ncbi.nlm.nih.gov/pubmed/20375806

149. Nagao, S., Miwa, M., Maeda, N., Kogiku, A., Yamamoto, K., Morimoto, A., et.al. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review, Int J Gynecol Cancer, 2015. 25(7): p. 1300-5., https://www.ncbi.nlm.nih.gov/pubmed/26166556

150. He, Y., Zhao, H., Li, X. M., Yin, C. H., Wu, Y. M., A clinical analysis of small-cell neuroendocrine carcinoma of the gynecologic tract: report of 20 cases, Arch Gynecol Obstet, 2019. 299(2): p. 543-549., https://www.ncbi.nlm.nih.gov/pubmed/30411160

151. Chan, J. K., Loizzi, V., Burger, R. A., Rutgers, J., Monk, B. J., Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis, Cancer, 2003. 97: p. 568-74., https://www.ncbi.nlm.nih.gov/pubmed/12548598

152. Schmidt, D., Horn, L. C., Kommoss, F., Neuroendocrine carcinomas of the cervix, Pathologe, 2005. 26: p. 262-5., https://www.ncbi.nlm.nih.gov/pubmed/15915327

153. Bhatla, N., Berek, J. S., Cuello Fredes, M., Denny, L. A., Grenman, S., Karunaratne, K., et.al. Revised FIGO staging for carcinoma of the cervix uteri, Int J Gynaecol Obstet, 2019. 145(1): p. 129-135., https://www.ncbi.nlm.nih.gov/pubmed/30656645

154. Bhatla, N., Berek, J. S., Cuello Fredes, M., Denny, L. A., Grenman, S., Karunaratne, K., et.al. Revised FIGO staging for carcinoma of the cervix uteri, Int J Gynaecol Obstet, 2019. 145(1): p. 129-135., https://www.ncbi.nlm.nih.gov/pubmed/30656645

155. Wright, J. D., Matsuo, K., Huang, Y., Tergas, A. I., Hou, J. Y., Khoury-Collado, F., et.al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines, Obstet Gynecol, 2019. 134(1): p. 49-57., https://www.ncbi.nlm.nih.gov/pubmed/31188324

156. Matsuo, K., Machida, H., Mandelbaum, R. S., Konishi, I., Mikami, M., Validation of the 2018 FIGO cervical cancer staging system, Gynecol Oncol, 2019. 152(1): p. 87-93., https://www.ncbi.nlm.nih.gov/pubmed/30389105

157. Nucci, M. R., Crum, C. P., Redefining early cervical neoplasia: recent progress, Adv Anat Pathol, 2007. 14: p. 1-10.

158. Dunn, M., Morgan, M. B., Beer, T. W., Perineural invasion: identification, significance, and a standardized definition, Dermatol Surg, 2009. 35: p. 214-21.

159. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., Albo, D., Perineural invasion in cancer: a review of the literature, Cancer, 2009. 115: p. 3379-91.

160. Wittekind, C, Compton, CC, Brirley, J, Sobin, LH, TNM Supplement. A Comentary on Uniform USeWiley-Blackwell, 2012.

161. Bosse, T., Peters, E. E., Creutzberg, C. L., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Mens, J. W., et.al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials, Eur J Cancer, 2015. 51(13): p. 1742-50., https://www.ncbi.nlm.nih.gov/pubmed/26049688

162. Peters, E. E. M., Bartosch, C., McCluggage, W. G., Genestie, C., Lax, S. F., Nout, R., et.al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer, Histopathology, 2019. 75(1): p. 128-136., https://www.ncbi.nlm.nih.gov/pubmed/31155736

163. Jesinghaus, M., Strehl, J., Boxberg, M., Bruhl, F., Wenzel, A., Konukiewitz, B., et.al. Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix, J Pathol Clin Res, 2018. 4(2): p. 93-102., https://www.ncbi.nlm.nih.gov/pubmed/29665323

164. Horn, L. C., Hohn, A. K., Hentschel, B., Fischer, U., Bilek, K., Brambs, C. E., Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas, J Cancer Res Clin Oncol, 2019. 145(2): p. 457-462., https://www.ncbi.nlm.nih.gov/pubmed/30603900

165. Brambs, C. E., Hohn, A. K., Hentschel, B., Fischer, U., Bilek, K., Horn, L. C., The Prognostic Impact of Grading in FIGO IB and IIB Squamous Cell Cervical Carcinomas, Geburtshilfe Frauenheilkd, 2019. 79(2): p. 198-204., https://www.ncbi.nlm.nih.gov/pubmed/30792550

166. Horn, L. C., Mayr, D., Brambs, C. E., Einenkel, J., Sandig, I., Schierle, K., [Grading of gynecological tumors : Current aspects], Pathologe, 2016. 37(4): p. 337-51., https://www.ncbi.nlm.nih.gov/pubmed/27379622

167. McCluggage, W. G., Judge, M. J., Alvarado-Cabrero, I., Duggan, M. A., Horn, L. C., Hui, P., et.al. Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR), Int J Gynecol Pathol, 2018. 37(3): p. 205-228., https://www.ncbi.nlm.nih.gov/pubmed/28700433

168. Hirschowitz, L., Sen, C., Murdoch, J., Primary endometrioid adenocarcinoma of the cervix with widespread squamous metaplasia--a potential diagnostic pitfall, Diagn Pathol, 2007. 2: p. 40.

169. Park, H. M., Lee, S. S., Eom, D. W., Kang, G. H., Yi, S. W., Sohn, W. S., Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix: a case report, J Korean Med Sci, 2009. 24(4): p. 767-71.

170. Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Terinte, C., Pesci, A., et.al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix, Am J Surg Pathol, 2018. 42(2): p. 214-226., https://www.ncbi.nlm.nih.gov/pubmed/29135516

171. Hodgson, A., Park, K. J., Djordjevic, B., Howitt, B. E., Nucci, M. R., Oliva, E., et.al. International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility, Am J Surg Pathol, 2019. 43(1): p. 75-83., https://www.ncbi.nlm.nih.gov/pubmed/29877920

172. Roma, A. A., Diaz De Vivar, A., Park, K. J., Alvarado-Cabrero, I., Rasty, G., Chanona-Vilchis, J. G., et.al. Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance, Am J Surg Pathol, 2015. 39(5): p. 667-72., https://www.ncbi.nlm.nih.gov/pubmed/25724003

173. Roma, A. A., Mistretta, T. A., Diaz De Vivar, A., Park, K. J., Alvarado-Cabrero, I., Rasty, G., et.al. New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome, Gynecol Oncol, 2016. 141(1): p. 36-42., https://www.ncbi.nlm.nih.gov/pubmed/27016227

174. Roma, A. A., Fadare, O., The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix, Virchows Arch, 2018. 472(6): p. 897-905., https://www.ncbi.nlm.nih.gov/pubmed/29404709

175. Stolnicu, S., Hoang, L., Soslow, R. A., Recent advances in invasive adenocarcinoma of the cervix, Virchows Arch, 2019. 475(5): p. 537-549., https://www.ncbi.nlm.nih.gov/pubmed/31209635

176. Horn, L. C., Mayr, D., Brambs, C. E., Einenkel, J., Sandig, I., Schierle, K., [Grading of gynecological tumors : Current aspects], Pathologe, 2016. 37(4): p. 337-51., https://www.ncbi.nlm.nih.gov/pubmed/27379622

177. Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Terinte, C., Pesci, A., et.al. Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV, Gynecol Oncol, 2018. 150(1): p. 56-60., https://www.ncbi.nlm.nih.gov/pubmed/29859673

178. Abu-Rustum, N. R., Yashar, C. M., Bean, S., Bradley, K., Campos, S. M., Chon, H. S., et.al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020, J Natl Compr Canc Netw, 2020. 18(6): p. 660-666., https://www.ncbi.nlm.nih.gov/pubmed/32502976

179. Darragh, T. M., Colgan, T. J., Thomas Cox, J., Heller, D. S., Henry, M. R., Luff, R. D., et.al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, Int J Gynecol Pathol, 2013. 32: p. 76-115.

180. Luo, Y. V., Prihoda, T. J., Sharkey, F. E., Number of levels needed for diagnosis of cervical biopsies, Arch Pathol Lab Med, 2002. 126: p. 1205-8.

181. Fadare, O., Rodriguez, R., Squamous dysplasia of the uterine cervix: tissue sampling-related diagnostic considerations in 600 consecutive biopsies, Int J Gynecol Pathol, 2007. 26: p. 469-74.

182. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration, Pathologe, 2007. 28: p. 249-60.

183. Kurman, R. J., Amin, M. B., Protocol for the examination of specimens from patients with carcinomas of the cervix: a basis for checklists. Cancer Committee, College of American Pathologists, Arch Pathol Lab Med, 1999. 123: p. 55-61.

184. Lawrence, W. D., ADASP recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease, Virchows Arch, 2001. 439: p. 601-3.

185. CAP, College of American Pathologists, 2013.

186. Girardi, F., Frey Tirri, B., Küppers, V., Menton, M., Quaas, J, Reich, O., Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011) - Approbierte Darstellung und Erläuterung für Deutschland, Österreich und die deutschsprachige Schweiz, FRAUENARZT, 2012. 53: p. 1064-1066.

187. Horn, L. C., Klostermann, K., Precancerous lesions of the uterine cervix: morphology and molecular pathology, Pathologe, 2011. 32 Suppl 2: p. 242-54.

188. ESGO, ESGO (2018). ESGO/ESTRO/ESP - Guidelines for Cervical Carcinoma., 2018., https://guidelines.esgo.org/media/2018/04/Cervical-cancer-Guidelines-Complete-report.pdf

189. Cibula, D., Potter, R., Planchamp, F., Avall-Lundqvist, E., Fischerova, D., Haie Meder, C., et.al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer, Int J Gynecol Cancer, 2018. 28(4): p. 641-655., https://www.ncbi.nlm.nih.gov/pubmed/29688967

190. Kristensen, G. B., Abeler, V. M., Risberg, B., Trop, C., Bryne, M., Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma, Gynecol Oncol, 1999. 74: p. 245-51.

191. Miroshnichenko, G. G., Parva, M., Holtz, D. O., Klemens, J. A., Dunton, C. J., Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision, J Low Genit Tract Dis, 2009. 13: p. 10-2.

192. Shin, J. W., Rho, H. S., Park, C. Y., Factors influencing the choice between cold knife conization and loop electrosurgical excisional procedure for the treatment of cervical intraepithelial neoplasia, J Obstet Gynaecol Res, 2009. 35: p. 126-30.

193. Reich, O., Pickel, H., Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions, Int J Gynecol Pathol, 2002. 21(4): p. 416-7.

194. McIlwaine, P., Nagar, H., McCluggage, W. G., Multifocal FIGO stage 1A1 cervical squamous carcinomas have an extremely good prognosis equivalent to unifocal lesions, Int J Gynecol Pathol, 2014. 33(3): p. 213-7., https://www.ncbi.nlm.nih.gov/pubmed/24681729

195. Day, E., Duffy, S., Bryson, G., Syed, S., Shanbhag, S., Burton, K., et.al. Multifocal FIGO Stage IA1 Squamous Carcinoma of the Cervix: Criteria for Identification, Staging, and its Good Clinical Outcome, Int J Gynecol Pathol, 2016. 35(5): p. 467-74., https://www.ncbi.nlm.nih.gov/pubmed/26863478

196. Darragh, T. M., Colgan, T. J., Thomas Cox, J., Heller, D. S., Henry, M. R., Luff, R. D., et.al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, Int J Gynecol Pathol, 2013. 32(1): p. 76-115., https://www.ncbi.nlm.nih.gov/pubmed/23202792

197. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration, Pathologe, 2007. 28: p. 249-60., https://www.ncbi.nlm.nih.gov/pubmed/16838175

198. Kurman, R. J., Amin, M. B., Protocol for the examination of specimens from patients with carcinomas of the cervix: a basis for checklists. Cancer Committee, College of American Pathologists, Arch Pathol Lab Med, 1999. 123: p. 55-61., https://www.ncbi.nlm.nih.gov/pubmed/9923838

199. Lawrence, W. D., ADASP recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease, Virchows Arch, 2001. 439: p. 601-3., https://www.ncbi.nlm.nih.gov/pubmed/11764377

201. Negri, G., Bellisano, G., Carico, E., Faa, G., Kasal, A., Antoniazzi, S., et.al. Usefulness of p16ink4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri, Int J Gynecol Pathol, 2011. 30: p. 407-13., https://www.ncbi.nlm.nih.gov/pubmed/21623205

202. Reuschenbach, M., Seiz, M., von Knebel Doeberitz, C., Vinokurova, S., Duwe, A., Ridder, R., et.al. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells, Int J Cancer, 2012. 130: p. 388-94., https://www.ncbi.nlm.nih.gov/pubmed/21387293

203. Horn, L. C., Klostermann, K., Precancerous lesions of the uterine cervix: morphology and molecular pathology, Pathologe, 2011. 32 Suppl 2: p. 242-54., https://www.ncbi.nlm.nih.gov/pubmed/21909794

204. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies, Pathologe, 2005. 26: p. 266-72., https://www.ncbi.nlm.nih.gov/pubmed/15915329

205. Horn, L. C., Höhn, A. K., Processing and Histopathological Workup of Hysterectomy Specimens, 2017., https://link.springer.com/chapter/10.1007/978-3-319-22497-8_18

206. Crockett, R. A., Sutton, S., Walter, F. M., Clinch, M., Marteau, T. M., Benson, J., Impact on decisions to start or continue medicines of providing information to patients about possible benefits and/or harms: a systematic review and meta-analysis, Med Decis Making, 2011. 31(5): p. 767-77., ThemenkomplexZ_H7

207. Alvarado-Cabrero, I., McCluggage, W. G., Estevez-Castro, R., Perez-Montiel, D., Stolnicu, S., Ganesan, R., et.al. Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases, Am J Surg Pathol, 2019. 43(6): p. 802-809., https://www.ncbi.nlm.nih.gov/pubmed/30864975

208. Ondic, O., Bouda, J., Nemejcova, K., Kajo, K., Hegedus, L., Alaghehbandan, R., On Histologic Variability of HPV-associated Endocervical Adenocarcinomas, Am J Surg Pathol, 2019. 43(6): p. 863-865., https://www.ncbi.nlm.nih.gov/pubmed/30994536

209. Horn, L. C., Handzel, R., Borte, G., Siebolts, U., Haak, A., Brambs, C. E., Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma, J Cancer Res Clin Oncol, 2019. 145(10): p. 2573-2582., https://www.ncbi.nlm.nih.gov/pubmed/31385027

211. RCP, RCP Royal College of Pathologists 2011.pdf

212. Kodama, J., Kusumoto, T., Nakamura, K., Seki, N., Hongo, A., Hiramatsu, Y., Factors associated with parametrial involvement in stage IB1 cervical cancer and identification of patients suitable for less radical surgery, Gynecol Oncol, 2011. 122: p. 491-4., https://www.ncbi.nlm.nih.gov/pubmed/21703671

213. Horn, L. C., Einenkel, J., Hockel, M., Kolbl, H., Kommoss, F., Lax, S. F., et.al. Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies, Pathologe, 2005. 26: p. 266-72.

214. Horn, L. C., Kellner, C., Scherling, R., Hockel, M., Einenkel, J., Ultrastaging for micrometastases in para-aortic lymph nodes in patients with carcinoma of the uterine cervix, Gynecol Oncol, 2012. 124: p. 374-5; author reply 375-6.

215. Hermanek, P., Hutter, R. V., Sobin, L. H., Wittekind, C., International Union Against Cancer. Classification of isolated tumor cells and micrometastasis, Cancer, 1999. 86: p. 2668-73.

216. Dostalek, L., Avall-Lundqvist, E., Creutzberg, C. L., Kurdiani, D., Ponce, J., Dostalkova, I., et.al. ESGO Survey on Current Practice in the Management of Cervical Cancer, Int J Gynecol Cancer, 2018. 28(6): p. 1226-1231., https://www.ncbi.nlm.nih.gov/pubmed/29958236

217. Vercellino, G. F., Erdemoglu, E., Lichtenberg, P., Muallem, M. Z., Richter, R., Abu-Rustum, N. R., et.al. A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer, Arch Gynecol Obstet, 2019. 300(1): p. 191-199., https://www.ncbi.nlm.nih.gov/pubmed/31006839

218. Rasty, G., Hauspy, J., Bandarchi, B., Assessment of sentinel lymph node in cervical cancer: review of literature, J Clin Pathol, 2009. 62: p. 1062-5., https://www.ncbi.nlm.nih.gov/pubmed/19748910

219. Dundr, P., Cibula, D., Nemejcova, K., Ticha, I., Bartu, M., Jaksa, R., Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer, Arch Pathol Lab Med, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31869245

220. Roy, M., Bouchard-Fortier, G., Popa, I., Gregoire, J., Renaud, M. C., Tetu, B., et.al. Value of sentinel node mapping in cancer of the cervix, Gynecol Oncol, 2011. 122: p. 269-74., https://www.ncbi.nlm.nih.gov/pubmed/21529908

221. Euscher, E. D., Malpica, A., Atkinson, E. N., Levenback, C. F., Frumovitz, M., Deavers, M. T., Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma, Am J Surg Pathol, 2008. 32: p. 1336-43., https://www.ncbi.nlm.nih.gov/pubmed/18670356

222. Guani, B., Dorez, M., Magaud, L., Buenerd, A., Lecuru, F., Mathevet, P., Impact of micrometastasis or isolated tumor cells on recurrence and survival in patients with early cervical cancer: SENTICOL Trial, Int J Gynecol Cancer, 2019. 29(3): p. 447-452., https://www.ncbi.nlm.nih.gov/pubmed/30833435

223. Kim, C. H., Abu-Rustum, N. R., Chi, D. S., Gardner, G. J., Leitao, M. M., Jr., Carter, J., et.al. Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer, Gynecol Oncol, 2012. 125(3): p. 585-8.

224. Horn, L. C., Brambs, C. E., Handzel, R., Lax, S., Sandig, I., Schmidt, D., et.al. [Cervical cancer : Update on morphology], Pathologe, 2016. 37(6): p. 542-548., https://www.ncbi.nlm.nih.gov/pubmed/27766382

225. Singh, N., Gilks, C. B., The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century, Histopathology, 2017. 70(1): p. 56-69., https://www.ncbi.nlm.nih.gov/pubmed/27960241

226. Kim, C. H., Soslow, R. A., Park, K. J., Barber, E. L., Khoury-Collado, F., Barlin, J. N., et.al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging, Int J Gynecol Cancer, 2013. 23(5): p. 964-70., https://www.ncbi.nlm.nih.gov/pubmed/23694985

227. Obrzut, B., Semczuk, A., Narog, M., Obrzut, M., Krol, P., Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up, Oncology, 2017. 93(2): p. 106-114., https://www.ncbi.nlm.nih.gov/pubmed/28463843

228. Suprasert, P., Srisomboon, J., Charoenkwan, K., Siriaree, S., Cheewakriangkrai, C., Kietpeerakool, C., et.al. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer, J Obstet Gynaecol, 2010. 30(3): p. 294-8.

229. Kasamatsu, T., Onda, T., Sawada, M., Kato, T., Ikeda, S., Sasajima, Y., et.al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix, Br J Cancer, 2009. 100(9): p. 1400-5.

230. Lee, Y. J., Kim, D. Y., Lee, S. W., Park, J. Y., Suh, D. S., Kim, J. H., et.al. A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection, Gynecol Oncol, 2017. 144(3): p. 536-540., https://www.ncbi.nlm.nih.gov/pubmed/28108027

231. Cohen, P. A., Jhingran, A., Oaknin, A., Denny, L., Cervical cancer, Lancet, 2019. 393(10167): p. 169-182., https://www.ncbi.nlm.nih.gov/pubmed/30638582

232. Lapuz, C., Kondalsamy-Chennakesavan, S., Bernshaw, D., Khaw, P., Narayan, K., Stage IB cervix cancer with nodal involvement treated with primary surgery or primary radiotherapy: Patterns of failure and outcomes in a contemporary population, J Med Imaging Radiat Oncol, 2016. 60(2): p. 274-82., https://www.ncbi.nlm.nih.gov/pubmed/26549207

233. Horn, L. C., Hentschel, B., Fischer, U., Peter, D., Bilek, K., Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact, Gynecol Oncol, 2008. 111: p. 276-81., https://www.ncbi.nlm.nih.gov/pubmed/18722005

234. Mabuchi, S., Okazawa, M., Kinose, Y., Matsuo, K., Fujiwara, M., Suzuki, O., et.al. Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy, Int J Gynecol Cancer, 2012. 22(8): p. 1389-97.

235. Khanna, N., Rauh, L. A., Lachiewicz, M. P., Horowitz, I. R., Margins for cervical and vulvar cancer, J Surg Oncol, 2016. 113(3): p. 304-9., https://www.ncbi.nlm.nih.gov/pubmed/26852901

236. Doll, K. M., Donnelly, E., Helenowski, I., Rosenbloom, L., Small, W., Jr., Schink, J. C., et.al. Radical hysterectomy compared with primary radiation for treatment of stage IB1 cervix cancer, Am J Clin Oncol, 2014. 37(1): p. 30-4., https://www.ncbi.nlm.nih.gov/pubmed/22992622

237. Samlal, R. A., van der Velden, J., Schilthuis, M. S., Gonzalez Gonzalez, D., Ten Kate, F. J., Hart, A. A., et.al. Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma, Gynecol Oncol, 1997. 64(3): p. 463-7.

238. Baalbergen, A., Ewing-Graham, P. C., Hop, W. C., Struijk, P., Helmerhorst, T. J., Prognostic factors in adenocarcinoma of the uterine cervix, Gynecol Oncol, 2004. 92: p. 262-7., https://www.ncbi.nlm.nih.gov/pubmed/14751169

239. Pieterse, Q. D., Kenter, G. G., Eilers, P. H., Trimbos, J. B., An individual prediction of the future (disease-free) survival of patients with a history of early-stage cervical cancer, multistate model, Int J Gynecol Cancer, 2008. 18: p. 432-8., https://www.ncbi.nlm.nih.gov/pubmed/17692087

240. Wagner, A. E., Pappas, L., Ghia, A. J., Gaffney, D. K., Impact of tumor size on survival in cancer of the cervix and validation of stage IIA1 and IIA2 subdivisions, Gynecol Oncol, 2013. 129(3): p. 517-21., https://www.ncbi.nlm.nih.gov/pubmed/23528928

241. Horn, L. C., Bilek, K., Fischer, U., Einenkel, J., Hentschel, B., A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer, Gynecol Oncol, 2014. 134(1): p. 42-6., https://www.ncbi.nlm.nih.gov/pubmed/24768850

242. Andikyan, V., Khoury-Collado, F., Denesopolis, J., Park, K. J., Hussein, Y. R., Brown, C. L., et.al. Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough?, Int J Gynecol Cancer, 2014. 24(1): p. 113-7., https://www.ncbi.nlm.nih.gov/pubmed/24335661

243. Emmett, M., Gildea, C., Nordin, A., Hirschowitz, L., Poole, J., Cervical cancer - does the morphological subtype affect survival rates?, J Obstet Gynaecol, 2018. 38(4): p. 548-555., https://www.ncbi.nlm.nih.gov/pubmed/29405083

244. Mabuchi, S., Okazawa, M., Matsuo, K., Kawano, M., Suzuki, O., Miyatake, T., et.al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma, Gynecol Oncol, 2012. 127: p. 114-20., https://www.ncbi.nlm.nih.gov/pubmed/22728518

245. Singh, N., Arif, S., Histopathologic parameters of prognosis in cervical cancer-a review, Int J Gynecol Cancer, 2004. 14: p. 741-50., https://www.ncbi.nlm.nih.gov/pubmed/15361180

246. Rose, P. G., Java, J. J., Whitney, C. W., Stehman, F. B., Lanciano, R., Thomas, G. M., Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation, Gynecol Oncol, 2014. 135(2): p. 208-12., https://www.ncbi.nlm.nih.gov/pubmed/25152438

247. Tewari, K. S., Sill, M. W., Long, H. J., 3rd, Penson, R. T., Huang, H., Ramondetta, L. M., et.al. Improved survival with bevacizumab in advanced cervical cancer, N Engl J Med, 2014. 370(8): p. 734-43., https://www.ncbi.nlm.nih.gov/pubmed/24552320

248. Winer, I., Alvarado-Cabrero, I., Hassan, O., Ahmed, Q. F., Alosh, B., Bandyopadhyay, S., et.al. The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study, Gynecol Oncol, 2015. 137(3): p. 474-8., https://www.ncbi.nlm.nih.gov/pubmed/25677061

249. Gadducci, A., Guerrieri, M. E., Cosio, S., Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables, Crit Rev Oncol Hematol, 2019. 135: p. 103-114., https://www.ncbi.nlm.nih.gov/pubmed/30819439

250. Stolnicu, S., Hoang, L., Chiu, D., Hanko-Bauer, O., Terinte, C., Pesci, A., et.al. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC), Am J Surg Pathol, 2019. 43(4): p. 466-474., https://www.ncbi.nlm.nih.gov/pubmed/30720532

251. Karamurzin, Y. S., Kiyokawa, T., Parkash, V., Jotwani, A. R., Patel, P., Pike, M. C., et.al. Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis, Am J Surg Pathol, 2015. 39(11): p. 1449-57., https://www.ncbi.nlm.nih.gov/pubmed/26457350

252. Stolnicu, S., Boros, M., Segura, S., Horn, L. C., Parra-Herran, C., Oliva, E., et.al. Invasive Stratified Mucinous Carcinoma (iSMC) of the Cervix Often Presents With High-risk Features That Are Determinants of Poor Outcome: An International Multicenter Study, Am J Surg Pathol, 2020.

253. Bean, S. M., Kurtycz, D. F., Colgan, T. J., Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix, J Low Genit Tract Dis, 2011. 15: p. 146-57., https://www.ncbi.nlm.nih.gov/pubmed/21317805

254. Cairns, M., Tidy, J., Cruickshank, M. E., Management of Microinvasive Cervical Cancer: A British Society for Colposcopy and Cervical Pathology Audit, J Low Genit Tract Dis, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22659775

255. Costa, S., Marra, E., Martinelli, G. N., Santini, D., Casadio, P., Formelli, G., et.al. Outcome of conservatively treated microinvasive squamous cell carcinoma of the uterine cervix during a 10-year follow-up, Int J Gynecol Cancer, 2009. 19: p. 33-8., https://www.ncbi.nlm.nih.gov/pubmed/19258938

256. Lee, K. B., Lee, J. M., Park, C. Y., Cho, H. Y., Ha, S. Y., Lymph node metastasis and lymph vascular space invasion in microinvasive squamous cell carcinoma of the uterine cervix, Int J Gynecol Cancer, 2006. 16: p. 1184-7., https://www.ncbi.nlm.nih.gov/pubmed/16803504

257. Margolis, B., Cagle-Colon, K., Chen, L., Tergas, A. I., Boyd, L., Wright, J. D., Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer, Int J Gynecol Cancer, 2020. 30(6): p. 735-743., https://www.ncbi.nlm.nih.gov/pubmed/32179697

258. Lim, C. S., Alexander-Sefre, F., Allam, M., Singh, N., Aleong, J. C., Al-Rawi, H., et.al. Clinical value of immunohistochemically detected lymphovascular space invasion in early stage cervical carcinoma, Ann Surg Oncol, 2008. 15: p. 2581-8., https://www.ncbi.nlm.nih.gov/pubmed/18622648

259. Creasman, W. T., Kohler, M. F., Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?, Gynecol Oncol, 2004. 92: p. 525-9., https://www.ncbi.nlm.nih.gov/pubmed/14766243

260. Qian, Y., Pollom, E. L., Nwachukwu, C., Seiger, K., von Eyben, R., Folkins, A. K., et.al. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma, Gynecol Oncol, 2017. 147(1): p. 24-29., https://www.ncbi.nlm.nih.gov/pubmed/28709703

261. Alvarado-Cabrero, I., Roma, A. A., Park, K. J., Rutgers, J. K. L., Silva, E. G., Factors Predicting Pelvic Lymph Node Metastasis, Relapse, and Disease Outcome in Pattern C Endocervical Adenocarcinomas, Int J Gynecol Pathol, 2017. 36(5): p. 476-485., https://www.ncbi.nlm.nih.gov/pubmed/28134668

262. Kristensen, G. B., Abeler, V. M., Risberg, B., Trop, C., Bryne, M., Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma, Gynecol Oncol, 1999. 74: p. 245-51., https://www.ncbi.nlm.nih.gov/pubmed/10419739

263. Stock, R. J., Zaino, R., Bundy, B. N., Askin, F. B., Woodward, J., Fetter, B., et.al. Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies, Int J Gynecol Pathol, 1994. 13: p. 99-108., https://www.ncbi.nlm.nih.gov/pubmed/8005742

264. Horn, L. C., Hohn, A. K., Hentschel, B., Fischer, U., Bilek, K., Brambs, C. E., Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas, J Cancer Res Clin Oncol, 2019. 145(2): p. 457-462., https://www.ncbi.nlm.nih.gov/pubmed/30603900

265. Satabongkoch, N., Khunamornpong, S., Pongsuvareeyakul, T., Settakorn, J., Sukpan, K., Soongkhaw, A., et.al. Prognostic Value of Tumor Budding in Early-Stage Cervical Adenocarcinomas, Asian Pac J Cancer Prev, 2017. 18(6): p. 1717-1722., https://www.ncbi.nlm.nih.gov/pubmed/28670894

266. Hockel, M., Horn, L. C., Tetsch, E., Einenkel, J., Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy, Gynecol Oncol, 2012. 125: p. 168-74., https://www.ncbi.nlm.nih.gov/pubmed/22155677

267. van Bommel, P. F., van Lindert, A. C., Kock, H. C., Leers, W. H., Neijt, J. P., A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy, Eur J Obstet Gynecol Reprod Biol, 1987. 26: p. 69-84., https://www.ncbi.nlm.nih.gov/pubmed/3311843

268. Horn, L. C., Meinel, A., Fischer, U., Bilek, K., Hentschel, B., Perineural invasion in carcinoma of the cervix uteri-prognostic impact, J Cancer Res Clin Oncol, 2010. 136: p. 1557-62., https://www.ncbi.nlm.nih.gov/pubmed/20169362

269. Cui, L., Shi, Y., Zhang, G. N., Perineural invasion as a prognostic factor for cervical cancer: a systematic review and meta-analysis, Arch Gynecol Obstet, 2015. 292(1): p. 13-9., https://www.ncbi.nlm.nih.gov/pubmed/25637504

270. Balega, J., Michael, H., Hurteau, J., Moore, D. H., Santiesteban, J., Sutton, G. P., et.al. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix, Int J Gynecol Cancer, 2004. 14: p. 104-9., https://www.ncbi.nlm.nih.gov/pubmed/14764037

271. Ho, C. M., Chien, T. Y., Huang, S. H., Wu, C. J., Shih, B. Y., Chang, S. C., Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy, Gynecol Oncol, 2004. 93: p. 458-64., https://www.ncbi.nlm.nih.gov/pubmed/15099962

272. Sartori, E., Tisi, G., Chiudinelli, F., La Face, B., Franzini, R., Pecorelli, S., Early stage cervical cancer: adjuvant treatment in negative lymph node cases, Gynecol Oncol, 2007. 107: p. S170-4., https://www.ncbi.nlm.nih.gov/pubmed/17765298

273. Sevin, B. U., Nadji, M., Lampe, B., Lu, Y., Hilsenbeck, S., Koechli, O. R., et.al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy, Cancer, 1995. 76: p. 1978-86., https://www.ncbi.nlm.nih.gov/pubmed/8634988

274. Fregnani, J. H., Latorre, M. R., Novik, P. R., Lopes, A., Soares, F. A., Assessment of pelvic lymph node micrometastatic disease in stages IB and IIA of carcinoma of the uterine cervix, Int J Gynecol Cancer, 2006. 16: p. 1188-94., https://www.ncbi.nlm.nih.gov/pubmed/16803505

275. Juretzka, M. M., Jensen, K. C., Longacre, T. A., Teng, N. N., Husain, A., Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis, Gynecol Oncol, 2004. 93: p. 107-11., https://www.ncbi.nlm.nih.gov/pubmed/15047221

276. Marchiole, P., Buenerd, A., Benchaib, M., Nezhat, K., Dargent, D., Mathevet, P., Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study, Gynecol Oncol, 2005. 97: p. 727-32., https://www.ncbi.nlm.nih.gov/pubmed/15943983

277. Cibula, D., Abu-Rustum, N. R., Dusek, L., Zikan, M., Zaal, A., Sevcik, L., et.al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer, Gynecol Oncol, 2012. 124: p. 496-501., https://www.ncbi.nlm.nih.gov/pubmed/22120175

278. Horn, L. C., Kellner, C., Scherling, R., Hockel, M., Einenkel, J., Ultrastaging for micrometastases in para-aortic lymph nodes in patients with carcinoma of the uterine cervix, Gynecol Oncol, 2012. 124: p. 374-5; author reply 375-6., https://www.ncbi.nlm.nih.gov/pubmed/22040833

279. Martinez, A., Mery, E., Ferron, G., Querleu, D., Incidence of micrometastases in histologically negative para-aortic lymph nodes in advanced cervical cancer patients, Gynecol Oncol, 2010. 119: p. 76-80., https://www.ncbi.nlm.nih.gov/pubmed/20667586

280. Zand, B., Euscher, E. D., Soliman, P. T., Schmeler, K. M., Coleman, R. L., Frumovitz, M., et.al. Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer, Gynecol Oncol, 2010. 119: p. 422-5., https://www.ncbi.nlm.nih.gov/pubmed/20837355

281. Rodriguez-Carunchio, L., Soveral, I., Steenbergen, R. D., Torne, A., Martinez, S., Fuste, P., et.al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis, BJOG, 2015. 122(1): p. 119-27., https://www.ncbi.nlm.nih.gov/pubmed/25229645

282. Omori, M., Hashi, A., Kondo, T., Katoh, R., Hirata, S., Dysregulation of CDK inhibitors and p53 in HPV-negative endocervical adenocarcinoma, Int J Gynecol Pathol, 2015. 34(2): p. 196-203., https://www.ncbi.nlm.nih.gov/pubmed/25675191

283. Ojesina, A. I., Lichtenstein, L., Freeman, S. S., Pedamallu, C. S., Imaz-Rosshandler, I., Pugh, T. J., et.al. Landscape of genomic alterations in cervical carcinomas, Nature, 2014. 506(7488): p. 371-5., https://www.ncbi.nlm.nih.gov/pubmed/24390348

284. Cancer Genome Atlas Research, Network, Albert Einstein College of, Medicine, Analytical Biological, Services, Barretos Cancer, Hospital, Baylor College of, Medicine, Beckman Research Institute of City of, Hope, et.al. Integrated genomic and molecular characterization of cervical cancer, Nature, 2017. 543(7645): p. 378-384., https://www.ncbi.nlm.nih.gov/pubmed/28112728

285. Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., et.al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix, Cancer, 2013. 119(21): p. 3776-83., https://www.ncbi.nlm.nih.gov/pubmed/24037752

286. Mirkovic, J., Sholl, L. M., Garcia, E., Lindeman, N., MacConaill, L., Hirsch, M., et.al. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract, Mod Pathol, 2015. 28(11): p. 1504-14., https://www.ncbi.nlm.nih.gov/pubmed/26336887

287. Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 2017. 357(6349): p. 409-413., https://www.ncbi.nlm.nih.gov/pubmed/28596308

288. Meng, Y., Liang, H., Hu, J., Liu, S., Hao, X., Wong, M. S. K., et.al. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer, J Cancer, 2018. 9(16): p. 2938-2945., https://www.ncbi.nlm.nih.gov/pubmed/30123362

289. Tewari, K. S., Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma, J Clin Oncol, 2019. 37(17): p. 1449-1454., https://www.ncbi.nlm.nih.gov/pubmed/31026210

290. Martinez, P., Del Campo, J. M., Pembrolizumab in recurrent advanced cervical squamous carcinoma, Immunotherapy, 2017. 9(6): p. 467-470., https://www.ncbi.nlm.nih.gov/pubmed/28399693

291. Kranawetter, M., Rohrich, S., Mullauer, L., Obermair, H., Reinthaller, A., Grimm, C., et.al. Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data, Int J Gynecol Cancer, 2018. 28(6): p. 1196-1202., https://www.ncbi.nlm.nih.gov/pubmed/29787422

292. Noordhuis, M. G., Eijsink, J. J., Roossink, F., de Graeff, P., Pras, E., Schuuring, E., et.al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review, Int J Radiat Oncol Biol Phys, 2011. 79: p. 325-34., https://www.ncbi.nlm.nih.gov/pubmed/21195874

293. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Filipits, M., Bartsch, R., Molecularly targeted therapies in cervical cancer. A systematic review, Gynecol Oncol, 2012. 126: p. 291-303., https://www.ncbi.nlm.nih.gov/pubmed/22504292

294. Dasari, S., Wudayagiri, R., Valluru, L., Cervical cancer: Biomarkers for diagnosis and treatment, Clin Chim Acta, 2015. 445: p. 7-11., https://www.ncbi.nlm.nih.gov/pubmed/25773118

295. Leath, C. A., 3rd, Monk, B. J., Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years, Gynecol Oncol, 2018. 150(3): p. 391-397., https://www.ncbi.nlm.nih.gov/pubmed/29954593

296. Minion, L. E., Tewari, K. S., Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition, Gynecol Oncol, 2018. 148(3): p. 609-621., https://www.ncbi.nlm.nih.gov/pubmed/29666026

297. Roszik, J., Ring, K. L., Wani, K. M., Lazar, A. J., Yemelyanova, A. V., Soliman, P. T., et.al. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy, Front Immunol, 2018. 9: p. 2102., https://www.ncbi.nlm.nih.gov/pubmed/30283446

298. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2018. 68(6): p. 394-424., https://www.ncbi.nlm.nih.gov/pubmed/30207593

299. GBA, AQUA Qualitätsreport 2012, 2013.

300. NCCN, NCCN Guideline 2.2013 Cervical Cancer.pdf, 2013.

301. Piver, M. S., Rutledge, F., Smith, J. P., Five classes of extended hysterectomy for women with cervical cancer, Obstet Gynecol, 1974. 44: p. 265-72.

302. Mota, F., Vergote, I., Trimbos, J. B., Amant, F., Siddiqui, N., Del Rio, A., et.al. Classification of radical hysterectomy adopted by the Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer, Int J Gynecol Cancer, 2008. 18: p. 1136-8.

303. Querleu, D., Morrow, C. P., Classification of radical hysterectomy, Lancet Oncol, 2008. 9: p. 297-303.

304. Trimbos, J. B., TNM-like classification of radical hysterectomy, Gynecol Oncol, 2009. 113: p. 397-8.

305. Ruscito, I., Gasparri, M. L., Braicu, E. I., Bellati, F., Raio, L., Sehouli, J., et.al. Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis, Ann Surg Oncol, 2016. 23(11): p. 3749-3756., https://www.ncbi.nlm.nih.gov/pubmed/27160526

306. Frumovitz, M., Plante, M., Lee, P. S., Sandadi, S., Lilja, J. F., Escobar, P. F., et.al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial, Lancet Oncol, 2018. 19(10): p. 1394-1403., https://www.ncbi.nlm.nih.gov/pubmed/30143441

307. Altgassen, C., Hertel, H., Brandstadt, A., Kohler, C., Durst, M., Schneider, A., et.al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group, J Clin Oncol, 2008. 26(18): p. 2943-51., http://www.ncbi.nlm.nih.gov/pubmed/18565880, http://jco.ascopubs.org/content/26/18/2943.full.pdf

308. Lande, J., Torrenga, B., Raijmakers, P. G., Hoekstra, O. S., Baal, M. W., Brolmann, H. A., et.al. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review (Provisional abstract), Gynecologic Oncology, 2007. 106: p. 604-613., https://www.ncbi.nlm.nih.gov/pubmed/17628644

309. Altgassen, C., Hertel, H., Brandstadt, A., Kohler, C., Durst, M., Schneider, A., et.al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group, J Clin Oncol, 2008. 26: p. 2943-51., https://www.ncbi.nlm.nih.gov/pubmed/18565880

310. Denschlag, D., Woll, J., Schneider, A., Stellenwert des Sentinel-Lymphknoten-Konzepts bei uterinen Karzinomen, Frauenarzt, 2011. 52: p. 46-51.

311. Selman, T. J., Mann, C., Zamora, J., Appleyard, T. L., Khan, K., Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis (Structured abstract), CMAJ: Canadian Medical Association Journal, 2008. 178: p. 855-862., https://www.ncbi.nlm.nih.gov/pubmed/18362381

312. Lecuru, F. R., McCormack, M., Hillemanns, P., Anota, A., Leitao, M., Mathevet, P., et.al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study, Int J Gynecol Cancer, 2019. 29(4): p. 829-834., https://www.ncbi.nlm.nih.gov/pubmed/30898938

313. Cibula, D., Abu-Rustum, N. R., Dusek, L., Slama, J., Zikan, M., Zaal, A., et.al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis, Gynecol Oncol, 2012. 127: p. 462-6., https://www.ncbi.nlm.nih.gov/pubmed/22943880

314. Tax, C., Rovers, M. M., de Graaf, C., Zusterzeel, P. L., Bekkers, R. L., The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review, Gynecol Oncol, 2015. 139(3): p. 559-67., https://www.ncbi.nlm.nih.gov/pubmed/26416173

315. Wang, X. J., Fang, F., Li, Y. F., Sentinel-lymph-node procedures in early stage cervical cancer: a systematic review and meta-analysis, Med Oncol, 2015. 32(1): p. 385., https://www.ncbi.nlm.nih.gov/pubmed/25429838

316. Kadkhodayan, S., Hasanzadeh, M., Treglia, G., Azad, A., Yousefi, Z., Zarifmahmoudi, L., et.al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature, Eur J Surg Oncol, 2015. 41(1): p. 1-20., https://www.ncbi.nlm.nih.gov/pubmed/25454828

317. Hockel, M., Horn, L. C., Manthey, N., Braumann, U. D., Wolf, U., Teichmann, G., et.al. Resection of the embryologically defined uterovaginal (Mullerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis, Lancet Oncol, 2009. 10(7): p. 683-92.

318. Hockel, M., Hentschel, B., Horn, L. C., Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis, Lancet Oncol, 2014. 15(4): p. 445-56., https://www.ncbi.nlm.nih.gov/pubmed/24656439

319. Marnitz, S., Kohler, C., Bongardt, S., Braig, U., Hertel, H., Schneider, A., et.al. Topographic distribution of sentinel lymph nodes in patients with cervical cancer, Gynecol Oncol, 2006. 103: p. 35-44., https://www.ncbi.nlm.nih.gov/pubmed/16600355

320. Charoenkwan, Kittipat, Kietpeerakool, Chumnan, Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignanciesJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353272/

321. Charoenkwan, Kittipat, Kietpeerakool, Chumnan, Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignanciesJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010.

322. Kim, H. S., Sardi, J. E., Katsumata, N., Ryu, H. S., Nam, J. H., Chung, H. H., et.al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis, Eur J Surg Oncol, 2013. 39: p. 115-24.

323. Rydzewska, L., Tierney, J., Vale, C. L., Symonds, P. R., Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer, Cochrane Database Syst Rev, 2012. 12: p. CD007406.

324. Rydzewska, L., Tierney, J., Vale, C. L., Symonds, P. R., Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer, Cochrane Database Syst Rev, 2012. 12: p. CD007406., https://www.ncbi.nlm.nih.gov/pubmed/20091632

325. Song, Y., Liu, Y., Lin, M., Sheng, B., Zhu, X., Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis, Drug Des Devel Ther, 2019. 13: p. 79-102., https://www.ncbi.nlm.nih.gov/pubmed/30587930

326. Peng, Y. H., Wang, X. X., Zhu, J. S., Gao, L., Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: Meta-analysis of randomized controlled trials, J Obstet Gynaecol Res, 2016. 42(2): p. 128-35., https://www.ncbi.nlm.nih.gov/pubmed/26807961

327. NCCN, NCCN Guideline 2.2013 Cervical Cancer.pdf, 2013.

328. AWMF, S2k Leitlinie Diagnostik und Therapie des Zervixkarzinoms, 2008.

329. Mota, F., Microinvasive squamous carcinoma of the cervix: treatment modalities, Acta Obstet Gynecol Scand, 2003. 82: p. 505-9.

330. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines) 1.2014 Cervical Cancer.pdf, 2014., http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

331. Kalliala, I., Nieminen, P., Dyba, T., Pukkala, E., Anttila, A., Cancer free survival after CIN treatment: comparisons of treatment methods and histology, Gynecol Oncol, 2007. 105: p. 228-33.

332. Martin-Hirsch, P. P., Paraskevaidis, E., Bryant, A., Dickinson, H. O., Keep, S. L., Surgery for cervical intraepithelial neoplasia, Cochrane Database Syst Rev, 2010. p. CD001318.

333. Mehlhorn, G., Lanowska, M., Thiel, F., Köhler, C., Beckmann, M.W., GebFra-Refresher: Organerhaltende operative Methoden im Bereich der Cervix uteri, Geburtsh Frauenheilk, 2008. 68: p. R121-R144.

334. Koch, M. C., Hautmann, S., Thiel, F., Beckmann, M. W., Mehlhorn, G., Ist die Messerkonisation mit anschließender Sturmdorfnaht Out? Gilt die Meinung: „Eine Messerkonisation macht heute kein Mensch mehr!?“ Wie ist der Stellenwert der Laserkonisation? Wie ist es mit der Bewertung der Schnittränder beim Lasern? Ist nicht beim Lasern der Aufwand viel zu hoch und teuer?, gynäkologische Praxis, 2014.

335. Wright, J. D., NathavithArana, R., Lewin, S. N., Sun, X., Deutsch, I., Burke, W. M., et.al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access, Obstet Gynecol, 2010. 115: p. 585-90.

336. Covens, A., Rosen, B., Murphy, J., Laframboise, S., DePetrillo, A. D., Lickrish, G., et.al. How important is removal of the parametrium at surgery for carcinoma of the cervix?, Gynecol Oncol, 2002. 84: p. 145-9.

337. Jolley, J. A., Battista, L., Wing, D. A., Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature, Am J Perinatol, 2007. 24: p. 531-9.

338. Schneider, A., Erdemoglu, E., Chiantera, V., Reed, N., Morice, P., Rodolakis, A., et.al. Clinical recommendation radical trachelectomy for fertility preservation in patients with early-stage cervical cancer, Int J Gynecol Cancer, 2012. 22: p. 659-66.

339. Smith, A. L., Frumovitz, M., Schmeler, K. M., dos Reis, R., Nick, A. M., Coleman, R. L., et.al. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?, Gynecol Oncol, 2010. 119: p. 183-6.

340. Suri, A., Frumovitz, M., Milam, M. R., dos Reis, R., Ramirez, P. T., Preoperative pathologic findings associated with residual disease at radical hysterectomy in women with stage IA2 cervical cancer, Gynecol Oncol, 2009. 112: p. 110-3.

341. Lee, S. W., Kim, Y. M., Son, W. S., You, H. J., Kim, D. Y., Kim, J. H., et.al. The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma, Acta Obstet Gynecol Scand, 2009. 88: p. 209-15.

342. Ang, C., Bryant, A., Barton, D. P., Pomel, C., Naik, R., Exenterative surgery for recurrent gynaecological malignancies, Cochrane Database Syst Rev, 2014. 2: p. CD010449.

343. Morelli, M., Venturella, R., Mocciaro, R., Di Cello, A., Rania, E., Lico, D., et.al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere, Gynecol Oncol, 2013. 129(3): p. 448-51., https://www.ncbi.nlm.nih.gov/pubmed/23558052

344. Van Lieshout, L. A. M., Pijlman, B., Vos, M. C., de Groot, M. J. M., Houterman, S., Coppus, Sfpj, et.al. Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial, Maturitas, 2018. 107: p. 1-6., https://www.ncbi.nlm.nih.gov/pubmed/29169572

345. Dietl, J., Wischhusen, J., Hausler, S. F., The post-reproductive Fallopian tube: better removed?, Hum Reprod, 2011. 26: p. 2918-24., https://www.ncbi.nlm.nih.gov/pubmed/21849300

346. Falconer, H., Yin, L., Gronberg, H., Altman, D., Ovarian cancer risk after salpingectomy: a nationwide population-based study, J Natl Cancer Inst, 2015. 107(2):, https://www.ncbi.nlm.nih.gov/pubmed/25628372

347. Kho, R. M., Wechter, M. E., Operative Outcomes of Opportunistic Bilateral Salpingectomy at the Time of Benign Hysterectomy in Low-Risk Premenopausal Women: A Systematic Review, J Minim Invasive Gynecol, 2017. 24(2): p. 218-229., https://www.ncbi.nlm.nih.gov/pubmed/27988392

348. Shimada, M., Kigawa, J., Nishimura, R., Yamaguchi, S., Kuzuya, K., Nakanishi, T., et.al. Ovarian metastasis in carcinoma of the uterine cervix, Gynecol Oncol, 2006. 101: p. 234-7., https://www.ncbi.nlm.nih.gov/pubmed/16300819

349. Ramirez, P. T., Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., et.al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer, N Engl J Med, 2018. 379(20): p. 1895-1904., https://www.ncbi.nlm.nih.gov/pubmed/30380365

350. Hillemanns, P., Brucker, S., Holthaus, B., Kimmig, R., Lampe, B., Runnebaum, I., et.al. Updated Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO) and the Gynecological Endoscopy Working Group (AGE) of the German Society of Gynecology and Obstetrics (DGGG) on the Randomized Study Comparing Minimally Invasive with Abdominal Radical Hysterectomy for Early-stage Cervical Cancer (LACC), Geburtshilfe Frauenheilkd, 2019. 79(2): p. 145-147., https://www.ncbi.nlm.nih.gov/pubmed/30792544

351. Melamed, A., Margul, D. J., Chen, L., Keating, N. L., Del Carmen, M. G., Yang, J., et.al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer, N Engl J Med, 2018. 379(20): p. 1905-1914., https://www.ncbi.nlm.nih.gov/pubmed/30379613

352. Cusimano, M. C., Baxter, N. N., Gien, L. T., Moineddin, R., Liu, N., Dossa, F., et.al. Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer, Am J Obstet Gynecol, 2019. 221(6): p. 619 e1-619 e24., https://www.ncbi.nlm.nih.gov/pubmed/31288006

353. L Chiva, V Zanagnolo, A Kucukmetin, G Chakalova, F Raspagliesi, F Narducci, et.al. SUCCOR study. An international european cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 (FIGO 2009, <4 cm) cervical cancer operated in 2013–2014, International Journal of Gynecological Cancer, 2019., https://ijgc.bmj.com/content/29/Suppl_4/A1

354. Jin, Y. M., Liu, S. S., Chen, J., Chen, Y. N., Ren, C. C., Robotic radical hysterectomy is superior to laparoscopic radical hysterectomy and open radical hysterectomy in the treatment of cervical cancer, PLoS One, 2018. 13(3): p. e0193033., https://www.ncbi.nlm.nih.gov/pubmed/29554090

355. Park, D. A., Yun, J. E., Kim, S. W., Lee, S. H., Surgical and clinical safety and effectiveness of robot-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy for cervical cancer: A systematic review and meta-analysis, Eur J Surg Oncol, 2017. 43(6): p. 994-1002., https://www.ncbi.nlm.nih.gov/pubmed/27546015

356. Wang, Y. Z., Deng, L., Xu, H. C., Zhang, Y., Liang, Z. Q., Laparoscopy versus laparotomy for the management of early stage cervical cancer, BMC Cancer, 2015. 15: p. 928., https://www.ncbi.nlm.nih.gov/pubmed/26596955

357. Kohler, C., Hertel, H., Herrmann, J., Marnitz, S., Mallmann, P., Favero, G., et.al. Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff - a multicenter analysis, Int J Gynecol Cancer, 2019. 29(5): p. 845-850., https://www.ncbi.nlm.nih.gov/pubmed/31155516

358. Morice, P., Rouanet, P., Rey, A., Romestaing, P., Houvenaeghel, G., Boulanger, J. C., et.al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer, Oncologist, 2012. 17: p. 64-71.

359. Chereau, E., C, De La Hosseraye, Ballester, M., Monnier, L., Rouzier, R., Touboul, E., et.al. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer, Anticancer Res, 2013. 33: p. 1661-6.

360. Darus, C. J., Callahan, M. B., Nguyen, Q. N., Pastore, L. M., Schneider, B. F., Rice, L. W., et.al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma, Int J Gynecol Cancer, 2008. 18: p. 730-5.

361. Colombo, P. E., Bertrand, M. M., Gutowski, M., Mourregot, A., Fabbro, M., Saint-Aubert, B., et.al. Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results, Gynecol Oncol, 2009. 114: p. 404-9.

362. Keys, Henry M., Bundy, Brian N., Stehman, Frederick B., Okagaki, Takashi, Gallup, Donald G., Burnett, Alexander F., et.al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group, Gynecologic Oncology, 2003. 89: p. 343-353.

363. Touboul, C., Uzan, C., Mauguen, A., Gouy, S., Rey, A., Pautier, P., et.al. Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer, Oncologist, 2010. 15: p. 405-15.

364. Lin, Y., Chen, K., Lu, Z., Zhao, L., Tao, Y., Ouyang, Y., et.al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis, Radiat Oncol, 2018. 13(1): p. 177., https://www.ncbi.nlm.nih.gov/pubmed/30217165

365. Du, X. L., Tao, J., Sheng, X. G., Lu, C. H., Yu, H., Wang, C., et.al. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy, Gynecol Oncol, 2012. 125(1): p. 151-7., https://www.ncbi.nlm.nih.gov/pubmed/22198339

366. Gandhi, A. K., Sharma, D. N., Rath, G. K., Julka, P. K., Subramani, V., Sharma, S., et.al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study, Int J Radiat Oncol Biol Phys, 2013. 87(3): p. 542-8., https://www.ncbi.nlm.nih.gov/pubmed/24074927

367. Ghadjar, P., Budach, V., Kohler, C., Jantke, A., Marnitz, S., Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation, Radiat Oncol, 2015. 10: p. 50., https://www.ncbi.nlm.nih.gov/pubmed/25890342

368. Marnitz, S., Wlodarczyk, W., Neumann, O., Koehler, C., Weihrauch, M., Budach, V., et.al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation - an intraindividual comparison, Radiat Oncol, 2015. 10: p. 91., https://www.ncbi.nlm.nih.gov/pubmed/25896675

369. Marnitz, S., Lukarski, D., Kohler, C., Wlodarczyk, W., Ebert, A., Budach, V., et.al. Helical tomotherapy versus conventional intensity-modulated radiation therapy for primary chemoradiation in cervical cancer patients: an intraindividual comparison, Int J Radiat Oncol Biol Phys, 2011. 81: p. 424-30., https://www.ncbi.nlm.nih.gov/pubmed/20864270

370. Portelance, L., Chao, K. S. C., Grigsby, P. W., Bennet, H., Low, D., Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation, International Journal of Radiation Oncology Biology Physics, 2001. 51: p. 261-266., https://www.ncbi.nlm.nih.gov/pubmed/11516876

371. Roeske, J. C., Lujan, A., Rotmensch, J., Waggoner, S. E., Yamada, D., Mundt, A. J., Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies, Int J Radiat Oncol Biol Phys, 2000. 48: p. 1613-21., https://www.ncbi.nlm.nih.gov/pubmed/11121668

372. Song, S., Rudra, S., Hasselle, M. D., Dorn, P. L., Mell, L. K., Mundt, A. J., et.al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy, Cancer, 2012., https://www.ncbi.nlm.nih.gov/pubmed/22806897

373. Marnitz, S., Martus, P., Kohler, C., Stromberger, C., Asse, E., Mallmann, P., et.al. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group, Int J Radiat Oncol Biol Phys, 2016. 94(2): p. 243-53., https://www.ncbi.nlm.nih.gov/pubmed/26853333

374. Manders, D. B., Sims, T. T., Bailey, A., Hwang, L., Richardson, D. L., Miller, D. S., et.al. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience, Am J Clin Oncol, 2018. 41(12): p. 1225-1230., https://www.ncbi.nlm.nih.gov/pubmed/29782361

375. Oh, J., Seol, K. H., Choi, Y. S., Lee, J. W., Bae, J. Y., Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy, Yeungnam Univ J Med, 2019. 36(2): p. 115-123., https://www.ncbi.nlm.nih.gov/pubmed/31620623

376. Judith, H. B., JRamon, A. H., Mario, B. T., Juan, G. G., Francisco, P., Randomized prospective trial of extended field radiation therapy versus pelvic radiation therapy alone and with chemotherapy for advanced cervical cancer, preliminary report., International Journal of Radiation Oncology Biology Physics, 1997. 39(2): p. 299-299.

377. Rotman, M., Pajak, T. F., Choi, K., Clery, M., Marcial, V., Grigsby, P. W., et.al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20, JAMA, 1995. 274(5): p. 387-93., https://www.ncbi.nlm.nih.gov/pubmed/7616634, https://jamanetwork.com/journals/jama/article-abstract/389343

378. Chantalat, E., Vidal, F., Leguevaque, P., Lepage, B., Mathevet, P., Deslandres, M., et.al. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers, Eur J Obstet Gynecol Reprod Biol, 2015. 193: p. 118-22., https://www.ncbi.nlm.nih.gov/pubmed/26295788

379. Jensen, L. G., Hasselle, M. D., Rose, B. S., Nath, S. K., Hasan, Y., Scanderbeg, D. J., et.al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin, Int J Gynecol Cancer, 2013. 23(1): p. 119-25., https://www.ncbi.nlm.nih.gov/pubmed/23262521

380. Lee, K., Lee, S., Choi, J., Park, S., Shin, J., Lee, K., et.al. Promising results of extended-field radiation therapy and high dose rate brachytherapy with concurrent platinum-based chemotherapy for uterine cervical cancer with para-aortic lymph node involvement, Ejc Supplements, 2007. 5(4): p. 323-323., https://www.researchgate.net/publication/238247752_5042_POSTER_Promising_results_of_extended-field_radiation_therapy_and_high_dose_rate_brachytherapy_with_concurrent_platinum-based_chemotherapy_for_uterine_cervical_cancer_with_para-aortic_lymph_node_i

381. Marnitz, S., Schram, J., Budach, V., Sackerer, I., Vercellino, G. F., Sehouli, J., et.al. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy, Strahlenther Onkol, 2015. 191(5): p. 421-8., https://www.ncbi.nlm.nih.gov/pubmed/25413986

382. Vargo, J. A., Kim, H., Choi, S., Sukumvanich, P., Olawaiye, A. B., Kelley, J. L., et.al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era, Int J Radiat Oncol Biol Phys, 2014. 90(5): p. 1091-8., https://www.ncbi.nlm.nih.gov/pubmed/25303889

383. Hwang, L., Bailey, A., Lea, J., Albuquerque, K., Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management, Future Oncol, 2015. 11(2): p. 309-22., https://www.ncbi.nlm.nih.gov/pubmed/25591841

384. Lim, K., Small, W., Jr., Portelance, L., Creutzberg, C., Jurgenliemk-Schulz, I. M., Mundt, A., et.al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer, Int J Radiat Oncol Biol Phys, 2011. 79: p. 348-55., https://www.ncbi.nlm.nih.gov/pubmed/20472347

385. Shaverdian, N., Gondi, V., Sklenar, K. L., Dunn, E. F., Petereit, D. G., Straub, M. R., et.al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer, Int J Radiat Oncol Biol Phys, 2013. 86(3): p. 562-8., https://www.ncbi.nlm.nih.gov/pubmed/23561652

386. Tanderup, K., Fokdal, L. U., Sturdza, A., Haie-Meder, C., Mazeron, R., van Limbergen, E., et.al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer, Radiother Oncol, 2016. 120(3): p. 441-446., https://www.ncbi.nlm.nih.gov/pubmed/27350396

387. Han, K., Milosevic, M., Fyles, A., Pintilie, M., Viswanathan, A. N., Trends in the utilization of brachytherapy in cervical cancer in the United States, Int J Radiat Oncol Biol Phys, 2013. 87(1): p. 111-9., https://www.ncbi.nlm.nih.gov/pubmed/23849695

388. Haie-Meder, C., Potter, R., Van Limbergen, E., Briot, E., De Brabandere, M., Dimopoulos, J., et.al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV, Radiother Oncol, 2005. 74(3): p. 235-45., https://www.ncbi.nlm.nih.gov/pubmed/15763303

389. Potter, R., Haie-Meder, C., Van Limbergen, E., Barillot, I., De Brabandere, M., Dimopoulos, J., et.al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology, Radiother Oncol, 2006. 78(1): p. 67-77.

390. Report 89, J ICRU, 2013. 13(1-2): p. NP., https://www.ncbi.nlm.nih.gov/pubmed/27335498

391. Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et.al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, Cochrane Database Syst Rev, 2005. p. CD002225., https://www.ncbi.nlm.nih.gov/pubmed/16034873

392. Wang, N., Guan, Q. L., Wang, K., Zhou, X., Gao, C., Yang, H. T., et.al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis (Structured abstract), Archives of Gynecology and Obstetrics, 2011. 283: p. 103-108., https://www.ncbi.nlm.nih.gov/pubmed/20157716

393. Lukka, H., Hirte, H., Fyles, A., Thomas, G., Elit, L., Johnston, M., et.al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis, Clin Oncol (R Coll Radiol), 2002. 14: p. 203-12., https://www.ncbi.nlm.nih.gov/pubmed/12109823

394. Rosa Daniela, D., Medeiros Lidia, R. F., Edelweiss Maria, I., Pohlmann Paula, R., Stein Airton, T., Adjuvant platinum-based chemotherapy for early stage cervical cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2012., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473195/

395. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010., https://www.ncbi.nlm.nih.gov/pubmed/19001332

396. Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et.al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, Cochrane Database Syst Rev, 2005. p. CD002225.

397. Wang, N., Guan, Q. L., Wang, K., Zhou, X., Gao, C., Yang, H. T., et.al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis (Structured abstract), Archives of Gynecology and Obstetrics, 2011. 283: p. 103-108.

398. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., 3rd, et.al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 1999. 340: p. 1154-61.

399. Morris, M., Eifel, P. J., Lu, J. D., Grigsby, P. W., Levenback, C., Stevens, R. E., et.al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, New England Journal of Medicine, 1999. 340: p. 1137-1143.

400. Peters, W.A., Liu, P.Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a Phase III inter group study, Soc Gynecol Oncol, 1999.

401. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., et.al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 1999. 340: p. 1144-53.

402. Whitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, W. C., Jr., et.al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, 1999. 17: p. 1339-48.

403. Lukka, H., Hirte, H., Fyles, A., Thomas, G., Elit, L., Johnston, M., et.al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis, Clin Oncol (R Coll Radiol), 2002. 14: p. 203-12.

404. Landoni, F., Maneo, A., Colombo, A., Placa, F., Milani, R., Perego, P., et.al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer, Lancet, 1997. 350: p. 535-40.

405. Moore, K. N., Gold, M. A., McMeekin, D. S., Zorn, K. K., Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma, Gynecol Oncol, 2007. 106: p. 498-501.

406. Gupta, S., Maheshwari, A., Parab, P., Mahantshetty, U., Hawaldar, R., Sastri Chopra, S., et.al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial, J Clin Oncol, 2018. 36(16): p. 1548-1555., https://www.ncbi.nlm.nih.gov/pubmed/29432076

407. G, Kenter, S, Greggi, Vergote, Ignace, al., et., Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994., J Clin Oncol, 2019. 37:

408. Zou, W., Han, Y., Zhang, Y., Hu, C., Feng, Y., Zhang, H., et.al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: A systematic review and meta-analysis, PLoS One, 2019. 14(11): p. e0225264., https://www.ncbi.nlm.nih.gov/pubmed/31725793

409. Marchetti, C., Fagotti, A., Tombolini, V., Scambia, G., De Felice, F., Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis, Cancer Treat Rev, 2020. 83: p. 101945., https://www.ncbi.nlm.nih.gov/pubmed/31838220

410. Tripathi, A., Rawat, S., Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix, J Obstet Gynaecol India, 2019. 69(6): p. 546-552., https://www.ncbi.nlm.nih.gov/pubmed/31844371

411. Rogers, Linda, Siu Shing Shun, N., Luesley, David, Bryant, Andrew, Dickinson Heather, O., Radiotherapy and chemoradiation after surgery for early cervical cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2012.

412. Sedlis, A., Bundy, B. N., Rotman, M. Z., Lentz, S. S., Muderspach, L. I., Zaino, R. J., A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study, Gynecol Oncol, 1999. 73: p. 177-83., https://www.ncbi.nlm.nih.gov/pubmed/10329031

413. Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., Liu, P. Y., et.al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial, Gynecologic Oncology, 2005. 96(3): p. 721-728., https://pubmed.ncbi.nlm.nih.gov/15721417/

414. Qin, A. Q., Liang, Z. G., Ye, J. X., Li, J., Wang, J. L., Chen, C. X., et.al. Significant Efficacy of Additional Concurrent Chemotherapy with Radiotherapy for Postoperative Cervical Cancer with Risk Factors: a Systematic Review and Meta-analysis, Asian Pac J Cancer Prev, 2016. 17(8): p. 3945-51., https://www.ncbi.nlm.nih.gov/pubmed/27644643

415. Tempfer, C. B., Tischoff, I., Dogan, A., Hilal, Z., Schultheis, B., Kern, P., et.al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature, BMC Cancer, 2018. 18(1): p. 530., https://www.ncbi.nlm.nih.gov/pubmed/29728073

416. Salvo, G., Gonzalez Martin, A., Gonzales, N. R., Frumovitz, M., Updates and management algorithm for neuroendocrine tumors of the uterine cervix, Int J Gynecol Cancer, 2019. 29(6): p. 986-995., https://www.ncbi.nlm.nih.gov/pubmed/31263021

417. Landoni, F., Colombo, A., Milani, R., Placa, F., Zanagnolo, V., Mangioni, C., Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update, J Gynecol Oncol, 2017. 28(3): p. e34., https://www.ncbi.nlm.nih.gov/pubmed/28382797

418. Carcopino, X., Houvenaeghel, G., Buttarelli, M., Esterni, B., Tallet, A., Goncalves, A., et.al. Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy, Eur J Surg Oncol, 2008. 34(5): p. 569-75., https://www.ncbi.nlm.nih.gov/pubmed/17531428

419. Haque, W., Verma, V., Butler, E. B., Teh, B. S., Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base, Anticancer Res, 2018. 38(5): p. 3175-3179., https://www.ncbi.nlm.nih.gov/pubmed/29715159

420. Shi, D., Liang, Z., Zhang, C., Zhang, H., Liu, X., The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis, BMC Cancer, 2018. 18(1): p. 308., https://www.ncbi.nlm.nih.gov/pubmed/29558900

421. Hass, P., Eggemann, H., Costa, S. D., Ignatov, A., Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer, Strahlenther Onkol, 2017. 193(12): p. 1048-1055., https://www.ncbi.nlm.nih.gov/pubmed/28660291

422. Huang, X. B., Zhang, W. W., Wu, S. G., Sun, J. Y., He, Z. Y., Zhou, J., Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix, J Surg Oncol, 2018. 118(3): p. 574-580., https://www.ncbi.nlm.nih.gov/pubmed/30114328

423. Platt, S. L., Patel, A., Humphrey, P. J., Al-Booz, H., Bailey, J., Completion surgery after chemoradiotherapy for cervical cancer - is there a role? UK Cancer Centre experience of hysterectomy post chemo-radiotherapy treatment for cervical cancer, J Obstet Gynaecol, 2019. 39(1): p. 68-73., https://www.ncbi.nlm.nih.gov/pubmed/30230397

424. Morice, P., Rouanet, P., Rey, A., Romestaing, P., Houvenaeghel, G., Boulanger, J. C., et.al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer, Oncologist, 2012. 17: p. 64-71., https://www.ncbi.nlm.nih.gov/pubmed/22234626

425. Shim, S. H., Kim, S. N., Chae, S. H., Kim, J. E., Lee, S. J., Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: a meta-analysis, J Gynecol Oncol, 2018. 29(2): p. e25., https://www.ncbi.nlm.nih.gov/pubmed/29400018

426. Gosset, M., Chargari, C., Bentivegna, E., Leary, A., Genestie, C., Maulard, A., et.al. Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?, Anticancer Res, 2019. 39(6): p. 2919-2926., https://www.ncbi.nlm.nih.gov/pubmed/31177130

427. Marnitz, S., Abt, E. C., Martus, P., Tsunoda, A., Kohler, C., Is Routine Curettage a Useful Tool to Evaluate Persistent Tumor in Patients Who Underwent Primary Chemoradiation for Locally Advanced and/or Lymph Node Positive Cervical Cancer?, Int J Gynecol Cancer, 2017. 27(6): p. 1216-1221., https://www.ncbi.nlm.nih.gov/pubmed/25950125

428. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2010.

429. Duenas-Gonzalez, A., Zarba, J. J., Patel, F., Alcedo, J. C., Beslija, S., Casanova, L., et.al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix, J Clin Oncol, 2011. 29: p. 1678-85.

430. Peters, W. A., 3rd, Liu, P. Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J Clin Oncol, 2000. 18: p. 1606-13.

431. Lorvidhaya, V., Chitapanarux, I., Sangruchi, S., Lertsanguansinchai, P., Kongthanarat, Y., Tangkaratt, S., et.al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1226-32.

432. Lorvidhaya, V., Chitapanarux, I., Sangruchi, S., Lertsanguansinchai, P., Kongthanarat, Y., Tangkaratt, S., et.al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1226-32., https://www.ncbi.nlm.nih.gov/pubmed/12654431

433. Ferrandina, G., Legge, F., Fagotti, A., Fanfani, F., Distefano, M., Morganti, A., et.al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures, Gynecol Oncol, 2007. 107: p. S127-32.

434. Mancuso, S., Smaniotto, D., Benedetti Panici, P., Favale, B., Greggi, S., Manfredi, R., et.al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma, Gynecol Oncol, 2000. 78: p. 324-8.

435. Mariagrazia, D., Anna, F., Gabriella, F., Francesco, F., Daniela, S., Giuseppe, D., et.al. Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications, Gynecol Oncol, 2005. 99: p. S166-70.

436. Shibata, K., Kikkawa, F., Suzuki, Y., Terauchi, M., Kajiyama, H., Ino, K., et.al. Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma, Gynecol Obstet Invest, 2004. 57: p. 93-9.

437. Wen, H., Wu, X., Li, Z., Wang, H., Zang, R., Sun, M., et.al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer, Int J Gynecol Cancer, 2012. 22: p. 296-302.

438. Gross, E., Champetier, C., Pointreau, Y., Zaccariotto, A., Duberge, T., Guerder, C., et.al. Normal tissue tolerance to external beam radiation therapy: ovaries, Cancer Radiother, 2010. 14: p. 373-5., https://www.ncbi.nlm.nih.gov/pubmed/20430663

439. Dittrich, R., Lotz, L., Hackl, J., Hildebrandt, T., Cupisti, S., Beckmann, M.W., Fertilitätserhalt bei Krebserkrankungen, Frauenarzt, 2014. 55(3): p. 240-246.

440. Hwang, J. H., Yoo, H. J., Park, S. H., Lim, M. C., Seo, S. S., Kang, S., et.al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy, Fertil Steril, 2012. 97: p. 1387-93 e1-2., https://www.ncbi.nlm.nih.gov/pubmed/22464082

441. Zhao, C., Wang, J. L., Wang, S. J., Zhao, L. J., Wei, L. H., Analysis of the risk factors for the recurrence of cervical cancer following ovarian transposition, Eur J Gynaecol Oncol, 2013. 34(2): p. 124-7., https://www.ncbi.nlm.nih.gov/pubmed/23781581

442. Nakanishi, T., Wakai, K., Ishikawa, H., Nawa, A., Suzuki, Y., Nakamura, S., et.al. A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix, Gynecol Oncol, 2001. 82(3): p. 504-9., http://www.ncbi.nlm.nih.gov/pubmed/11520147

443. Small, W., Jr., Beriwal, S., Demanes, D. J., Dusenbery, K. E., Eifel, P., Erickson, B., et.al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy, Brachytherapy, 2012. 11: p. 58-67.

444. Gemignani, M. L., Alektiar, K. M., Leitao, M., Mychalczak, B., Chi, D., Venkatraman, E., et.al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers, Int J Radiat Oncol Biol Phys, 2001. 50: p. 687-94.

445. Giorda, G., Boz, G., Gadducci, A., Lucia, E., De Piero, G., De Paoli, A., et.al. Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy. A phase II trial, Eur J Surg Oncol, 2011. 37: p. 442-7.

446. Jurado, M., Martinez-Monge, R., Garcia-Foncillas, J., Azinovic, I., Aristu, J., Lopez-Garcia, G., et.al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery, intraoperative electron beam radiotherapy in locally advanced cervical cancer, Gynecol Oncol, 1999. 74: p. 30-7.

447. Mahe, M. A., Gerard, J. P., Dubois, J. B., Roussel, A., Bussieres, E., Delannes, M., et.al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients, Int J Radiat Oncol Biol Phys, 1996. 34: p. 21-6.

448. Tran, P. T., Su, Z., Hara, W., Husain, A., Teng, N., Kapp, D. S., Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies, Int J Radiat Oncol Biol Phys, 2007. 69: p. 504-11.

449. Winter, W. E., 3rd, Maxwell, G. L., Tian, C., Sobel, E., Rose, G. S., Thomas, G., et.al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study, Gynecol Oncol, 2004. 94: p. 495-501., https://www.ncbi.nlm.nih.gov/pubmed/15297194

450. Dunst, J., Kuhnt, T., Strauss, H. G., Krause, U., Pelz, T., Koelbl, H., et.al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis, Int J Radiat Oncol Biol Phys, 2003. 56: p. 778-87., https://www.ncbi.nlm.nih.gov/pubmed/12788185

451. Fyles, A. W., Milosevic, M., Pintilie, M., Syed, A., Hill, R. P., Anemia, hypoxia and transfusion in patients with cervix cancer: a review, Radiother Oncol, 2000. 57: p. 13-9., https://www.ncbi.nlm.nih.gov/pubmed/11033184

452. Bishop, A. J., Allen, P. K., Klopp, A. H., Meyer, L. A., Eifel, P. J., Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?, Int J Radiat Oncol Biol Phys, 2015. 91(1): p. 196-205., https://www.ncbi.nlm.nih.gov/pubmed/25446609

453. Thomas, G., Ali, S., Hoebers, F. J., Darcy, K. M., Rodgers, W. H., Patel, M., et.al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer, Gynecol Oncol, 2008. 108: p. 317-25., https://www.ncbi.nlm.nih.gov/pubmed/18037478

454. Strauss, H. G., Haensgen, G., Dunst, J., Hayward, C. R., Burger, H. U., Scherhag, A., et.al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer, Int J Gynecol Cancer, 2008. 18: p. 515-24., https://www.ncbi.nlm.nih.gov/pubmed/17645506

455. Gupta, S., Singh, P. K., Bisth, S. S., Bhatt, M. L., Pant, M., Gupta, R., et.al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy", Cancer Biol Ther, 2009. 8: p. 13-7., https://www.ncbi.nlm.nih.gov/pubmed/18981719

456. Blohmer, J. U., Paepke, S., Sehouli, J., Boehmer, D., Kolben, M., Wurschmidt, F., et.al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study, J Clin Oncol, 2011. 29: p. 3791-7.

457. Lutgens, L., van der Zee, J., Pijls-Johannesma, M., De Haas-Kock, D. F., Buijsen, J., Mastrigt, G. A., et.al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma, Cochrane Database Syst Rev, 2010. p. CD006377., https://www.ncbi.nlm.nih.gov/pubmed/20091593

458. Harima, Y., Ohguri, T., Imada, H., Sakurai, H., Ohno, T., Hiraki, Y., et.al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer, Int J Hyperthermia, 2016. 32(7): p. 801-8., https://www.ncbi.nlm.nih.gov/pubmed/27418208

459. Ohguri, T., Harima, Y., Imada, H., Sakurai, H., Ohno, T., Hiraki, Y., et.al. Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial, Int J Hyperthermia, 2018. 34(4): p. 461-468., https://www.ncbi.nlm.nih.gov/pubmed/28679349

460. Richel, O., Zum Vorde Sive Vording, P. J., Rietbroek, R., Van der Velden, J., Van Dijk, J. D., Schilthuis, M. S., et.al. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer, Gynecol Oncol, 2004. 95(3): p. 680-5.

461. Bruggmoser, G., Bauchowitz, S., Canters, R., Crezee, H., Ehmann, M., Gellermann, J., et.al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia, Strahlenther Onkol, 2012. 188 Suppl 2: p. 198-211., https://www.ncbi.nlm.nih.gov/pubmed/22926657

462. Chung, H. C., Ros, W., Delord, J. P., Perets, R., Italiano, A., Shapira-Frommer, R., et.al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol, 2019. 37(17): p. 1470-1478., https://www.ncbi.nlm.nih.gov/pubmed/30943124

463. Keys, H. M., Bundy, B. N., Stehman, F. B., Muderspach, L. I., Chafe, W. E., Suggs, C. L., 3rd, et.al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 1999. 340: p. 1154-61., https://www.ncbi.nlm.nih.gov/pubmed/10202166

464. Morris, M., Eifel, P. J., Lu, J. D., Grigsby, P. W., Levenback, C., Stevens, R. E., et.al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, New England Journal of Medicine, 1999. 340: p. 1137-1143., https://www.ncbi.nlm.nih.gov/pubmed/10202164

465. Peters, W.A., Liu, P.Y., Barrett, R. J., 2nd, Stock, R. J., Monk, B. J., Berek, J. S., et.al. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a Phase III inter group study, Soc Gynecol Oncol, 1999., https://www.ncbi.nlm.nih.gov/pubmed/10764420

466. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., et.al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 1999. 340: p. 1144-53., https://www.ncbi.nlm.nih.gov/pubmed/10202165

467. Whitney, C. W., Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, W. C., Jr., et.al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, 1999. 17: p. 1339-48., https://www.ncbi.nlm.nih.gov/pubmed/10334517

468. Group, Meta-Analysis, Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials, J Clin Oncol, 2008. 26: p. 5802-12., https://www.ncbi.nlm.nih.gov/pubmed/19001332

469. Ryu, S. Y., Park, S. I., Nam, B. H., Cho, C. K., Kim, K., Kim, B. J., et.al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?, Int J Radiat Oncol Biol Phys, 2011. 79: p. 794-9., https://www.ncbi.nlm.nih.gov/pubmed/20421158

470. Greer, B. E., Koh, W. J., Abu-Rustum, N. R., Apte, S. M., Campos, S. M., Chan, J., et.al. Cervical cancer, J Natl Compr Canc Netw, 2010. 8: p. 1388-416., https://www.ncbi.nlm.nih.gov/pubmed/21147903

471. S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen - Langversion 1.3 – Februar 2020 AWMF-Registernummer: 032/054OL, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.3.pdf

472. Katsumata, N., Yoshikawa, H., Kobayashi, H., Saito, T., Kuzuya, K., Nakanishi, T., et.al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102), Br J Cancer, 2013. 108(10): p. 1957-63., https://www.ncbi.nlm.nih.gov/pubmed/23640393

473. Yang, Z., Chen, D., Zhang, J., Yao, D., Gao, K., Wang, H., et.al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study, Gynecologic oncology, 2016. 141(2): p. 231-239., https://www.sciencedirect.com/science/article/pii/S0090825815300482?via%3Dihub

474. He, D., Duan, C., Chen, J., Lai, L., Chen, J., Chen, D., The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis, Int J Clin Exp Med, 2015. 8(9): p. 14693-700., https://www.ncbi.nlm.nih.gov/pubmed/26628951

475. Zhu, Y., Yang, J., Zhang, X., Chen, D., Zhang, S., Acquired treatment response from neoadjuvant chemotherapy predicts a favorable prognosis for local advanced cervical cancer: A meta-analysis, Medicine (Baltimore), 2018. 97(17): p. e0530., https://www.ncbi.nlm.nih.gov/pubmed/29703026

476. Ye, Q., Yuan, H. X., Chen, H. L., Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis, J Cancer Res Clin Oncol, 2013. 139(11): p. 1887-98., https://www.ncbi.nlm.nih.gov/pubmed/24022086

477. Chen, Z., Shi, Y., Wang, S., Lu, Q., Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients, Oncotarget, 2017. 8(35): p. 59609-59617., https://www.ncbi.nlm.nih.gov/pubmed/28938664

478. He, L., Wu, L., Su, G., Wei, W., Liang, L., Han, L., et.al. The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer, Gynecol Oncol, 2014. 134(2): p. 419-25., https://www.ncbi.nlm.nih.gov/pubmed/24918866

479. Laios, A., Kasius, J., Tranoulis, A., Gryparis, A., Ind, T., Obstetric Outcomes in Women With Early Bulky Cervical Cancer Downstaged by Neoadjuvant Chemotherapy to Allow for Fertility-Sparing Surgery: A Meta-analysis and Metaregression, Int J Gynecol Cancer, 2018. 28(4): p. 794-801., https://www.ncbi.nlm.nih.gov/pubmed/29538257

480. Kim, H. S., Sardi, J. E., Katsumata, N., Ryu, H. S., Nam, J. H., Chung, H. H., et.al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis, Eur J Surg Oncol, 2013. 39(2): p. 115-24., https://www.ncbi.nlm.nih.gov/pubmed/23084091

481. Tzioras, S., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P., Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis, Cancer Treat Rev, 2007. 33: p. 24-38., https://www.ncbi.nlm.nih.gov/pubmed/17112673

482. Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., et.al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study, J Clin Oncol, 2009. 27: p. 4649-55., https://www.ncbi.nlm.nih.gov/pubmed/19720909

483. Scatchard, K., Forrest, J. L., Flubacher, M., Cornes, P., Williams, C., Chemotherapy for metastatic and recurrent cervical cancer, Cochrane Database Syst Rev, 2012. 10: p. CD006469., https://www.ncbi.nlm.nih.gov/pubmed/23076924

484. Long, H. J., 3rd, Bundy, B. N., Grendys, E. C., Jr., Benda, J. A., McMeekin, D. S., Sorosky, J., et.al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study, J Clin Oncol, 2005. 23: p. 4626-33., https://www.ncbi.nlm.nih.gov/pubmed/15911865

485. Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., et.al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240), Lancet, 2017. (no pagination):, https://www.sciencedirect.com/science/article/pii/S0140673617316070

486. Kitagawa, R., Katsumata, N., Shibata, T., Kamura, T., Kasamatsu, T., Nakanishi, T., et.al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. 33(19): p. 2129-35., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/694/CN-01085694/frame.html

487. Rosen, V. M., Guerra, I., McCormack, M., Nogueira-Rodrigues, A., Sasse, A., Munk, V. C., et.al. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer, Int J Gynecol Cancer, 2017. 27(6): p. 1237-1246., https://www.ncbi.nlm.nih.gov/pubmed/28448304

488. Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., et.al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants, J Clin Oncol, 2009. 27: p. 127-45., https://www.ncbi.nlm.nih.gov/pubmed/19018081

489. S2k Leitlinie Diagnostik und Therapie der Lymphödeme AWMF Reg.-Nr. 058-001 - Mai 2017, https://www.awmf.org/uploads/tx_szleitlinien/058-001l_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2019-07.pdf

490. Miles, T., Johnson, N., Vaginal dilator therapy for women receiving pelvic radiotherapy, Cochrane Database Syst Rev, 2014. p. CD007291., https://www.ncbi.nlm.nih.gov/pubmed/25198150

491. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50(5): p. 440-7., http://www.ncbi.nlm.nih.gov/pubmed/19855028, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902246/pdf/nihms206794.pdf

492. Hodgkinson, K., Butow, P., Fuchs, A., Hunt, G. E., Stenlake, A., Hobbs, K. M., et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes, Gynecol Oncol, 2007. 104(2): p. 381-9., http://www.ncbi.nlm.nih.gov/pubmed/17027072, http://ac.els-cdn.com/S0090825806006950/1-s2.0-S0090825806006950-main.pdf?_tid=3dd52058-0c84-11e2-b8cf-00000aab0f01&acdnat=1349177468_b43b7f7661c9e2064936adbc48020c07

493. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16(3): p. 222-30., http://www.ncbi.nlm.nih.gov/pubmed/17508941, http://onlinelibrary.wiley.com/store/10.1111/j.1365-2354.2006.00744.x/asset/j.1365-2354.2006.00744.x.pdf?v=1&t=h7sxgt3o&s=631316f577660a43befe7c7a7f62362d9817e6dc

494. Roth, A. J., Carter, J., Nelson, C. L., Sexuality after CancerOxford University Press, Psycho-Oncology, 2010.

495. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31(4): p. 284-91., http://www.ncbi.nlm.nih.gov/pubmed/18600115

496. Klee, M., Thranov, I., Machin Prof, D., The patients' perspective on physical symptoms after radiotherapy for cervical cancer, Gynecol Oncol, 2000. 76(1): p. 14-23., http://www.ncbi.nlm.nih.gov/pubmed/10620435, http://ac.els-cdn.com/S0090825899956421/1-s2.0-S0090825899956421-main.pdf?_tid=61d1cdd0-0c84-11e2-9b70-00000aab0f02&acdnat=1349177529_c5fdde9c6579f3b3fed1e72aa1eaaf60

498. Steele, R., Fitch, M. I., Supportive care needs of women with gynecologic cancer, Cancer Nurs, 2008. 31: p. 284-91., https://www.ncbi.nlm.nih.gov/pubmed/18600115

499. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22: p. 1369-81., https://www.ncbi.nlm.nih.gov/pubmed/8539178

500. Roth, A. J., Carter, J., Nelson, C. L., Sexuality after CancerOxford University Press, Psycho-Oncology, 2010.

501. Kaufmann, M., Ernst, B., Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen, Deutsches Ärzteblatt, 2000. 47: p. 191-196.

502. Leitlinienprogramm_Onkologie, S3 Leitlinie "Psychoonkologische Diagnostik, Beratung und Behandlung von Krebspatienten“ (AWMF-Registernummer 032 - 051OL), 2014., http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/032-051OL.html

503. Herschbach, P., Weis, J., Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten, Deutsche Krebsgesellschaft Berlin, 2010. 2. Auflage:

504. Mehnert, A., Lehmann, C., Cao, P., Koch, U., [Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments], Psychother Psychosom Med Psychol, 2006. 56(12): p. 462-79., http://www.ncbi.nlm.nih.gov/pubmed/17160791

505. Leitlinienprogramm_Onkologie, S3 Leitlinie "Psychoonkologische Diagnostik, Beratung und Behandlung von Krebspatienten“ (AWMF-Registernummer 032 - 051OL), 2014., http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/032-051OL.html

506. Chan, Y. M., Lee, P. W., Fong, D. Y., Fung, A. S., Wu, L. Y., Choi, A. Y., et.al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial, J Clin Oncol, 2005. 23(22): p. 4913-24., http://www.ncbi.nlm.nih.gov/pubmed/15939927, http://jco.ascopubs.org/content/23/22/4913.full.pdf

507. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2008. 17(4): p. 392-400., http://www.ncbi.nlm.nih.gov/pubmed/17680554, http://onlinelibrary.wiley.com/store/10.1002/pon.1249/asset/1249_ftp.pdf?v=1&t=h7sx6l4l&s=53663234d2659474db4501a38c3c18853cec11dd

508. Brown, L. F., Kroenke, K., Cancer-related fatigue and its associations with depression and anxiety: a systematic review, Psychosomatics, 2009. 50: p. 440-7., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902246/

509. Hodgkinson, K., Butow, P., Fuchs, A., Hunt, G. E., Stenlake, A., Hobbs, K. M., et.al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes, Gynecol Oncol, 2007. 104: p. 381-9., https://www.ncbi.nlm.nih.gov/pubmed/17027072

510. Reuter, K., Raugust, S., Marschner, N., Harter, M., Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynaecological cancer, Eur J Cancer Care (Engl), 2007. 16: p. 222-30., https://www.ncbi.nlm.nih.gov/pubmed/17508941

511. Klee, M., Thranov, I., Machin Prof, D., The patients perspective on physical symptoms after radiotherapy for cervical cancer, Gynecol Oncol, 2000. 76: p. 14-23., https://www.ncbi.nlm.nih.gov/pubmed/10620435

512. Li, C., Samsioe, G., Iosif, C., Quality of life in endometrial cancer survivors, Maturitas, 1999. 31: p. 227-36., https://www.ncbi.nlm.nih.gov/pubmed/10340282

513. Radoschewski, M., Gesundheitsbezogene Lebensqualität – Konzepte und Maße: Entwicklungen und Stand im Überblick, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2000. 43(3): p. 165-189.

514. Ang, C., Bryant, A., Barton, D. P., Pomel, C., Naik, R., Exenterative surgery for recurrent gynaecological malignancies, Cochrane Database Syst Rev, 2014. 2: p. CD010449., https://www.ncbi.nlm.nih.gov/pubmed/24497188

515. Rosen, V. M., Guerra, I., McCormack, M., Nogueira-Rodrigues, A., Sasse, A., Munk, V. C., et.al. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer, Int J Gynecol Cancer, 2017. 27(6): p. 1237-1246., https://www.ncbi.nlm.nih.gov/pubmed/28448304

516. Chung, H. C., Ros, W., Delord, J. P., Perets, R., Italiano, A., Shapira-Frommer, R., et.al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol, 2019. 37(17): p. 1470-1478., https://www.ncbi.nlm.nih.gov/pubmed/30943124

517. Roth, A. J., Carter, J., Nelson, C. L., Sexuality after CancerOxford University Press, Psycho-Oncology, 2010.

518. Kaufmann, M., Ernst, B., Was Frauen mit Krebs erfahren, empfinden, wissen und vermissen, Deutsches Ärzteblatt, 2000. 47: p. 191-196.

519. Herschbach, P., Weis, J., Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten, Deutsche Krebsgesellschaft Berlin, 2010. 2. Auflage:

520. Mehnert, A., Lehmann, C., Cao, P., Koch, U., Assessment of psychosocial distress and resources in oncology--a literature review about screening measures and current developments, Psychother Psychosom Med Psychol, 2006. 56: p. 462-79., https://www.ncbi.nlm.nih.gov/pubmed/17160791

521. Beesley, V., Eakin, E., Steginga, S., Aitken, J., Dunn, J., Battistutta, D., Unmet needs of gynaecological cancer survivors: implications for developing community support services, Psychooncology, 2008. 17: p. 392-400., https://www.ncbi.nlm.nih.gov/pubmed/17680554

522. Radoschewski, M., Gesundheitsbezogene Lebensqualität - Konzepte und Maße: Entwicklungen und Stand im Überblick, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2000. 43: p. 165-189.

523. Hack, C, Integrative Medizin in der Gynäkologischen Onkologie, Geburtsh Frauenheilk, 2013. 73: p. R65-R80.

524. Horneber, M., Bueschel, G., Dennert, G., Less, D., Ritter, E., Zwahlen, M., How Many Cancer Patients Use Complementary and Alternative Medicine: A Systematic Review and Metaanalysis, Integr Cancer Ther, 2011., https://www.ncbi.nlm.nih.gov/pubmed/22019489

525. Consortion of Academic Health Centers for Integrative Medicine 2019:, https://imconsortium.org/about/introduction/

526. McKay, D. J., Bentley, J. R., Grimshaw, R. N., Complementary and alternative medicine in gynaecologic oncology, J Obstet Gynaecol Can, 2005. 27: p. 562-8., https://www.ncbi.nlm.nih.gov/pubmed/16100633

527. Greenwald, H. P., McCorkle, R., Remedies and life changes among invasive cervical cancer survivors, Urol Nurs, 2007. 27: p. 47-53., https://www.ncbi.nlm.nih.gov/pubmed/17390927

528. Hubner, J., Muenstedt, K., Muecke, R., Micke, O., Stoll, C., Kleeberg, U. R., et.al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities, Strahlenther Onkol, 2013. 189: p. 613-7., https://www.ncbi.nlm.nih.gov/pubmed/23824107

529. Nagy, V., Todor, N., Coza, O., Ordeanu, C., Ghilezan, N., Quality of life and treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens, J BUON, 2007. 12: p. 389-94., https://www.ncbi.nlm.nih.gov/pubmed/17918294

530. Braun, S., Reimer, D., Strobl, I., Wieland, U., Wiesbauer, P., Muller-Holzner, E., et.al. Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report, J Med Case Rep, 2011. 5: p. 316., https://www.ncbi.nlm.nih.gov/pubmed/21767367

531. Jenkins, C. A., Scarfe, A., Bruera, E., Integration of palliative care with alternative medicine in patients who have refused curative cancer therapy: a report of two cases, J Palliat Care, 1998. 14: p. 55-9., https://www.ncbi.nlm.nih.gov/pubmed/9893400

532. BfArM-Stellungnahme vom 28.11.2011, 2011. 2013:, http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/2011/RI-ukrain.html

534. Han, E., Johnson, N., DelaMelena, T., Glissmeyer, M., Steinbock, K., Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes, Ann Surg Oncol, 2011. 18: p. 912-6., https://www.ncbi.nlm.nih.gov/pubmed/21225354

535. Bagenal, F. S., Easton, D. F., Harris, E., Chilvers, C. E., McElwain, T. J., Survival of patients with breast cancer attending Bristol Cancer Help Centre, Lancet, 1990. 336: p. 606-10., https://www.ncbi.nlm.nih.gov/pubmed/1975387

536. Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., Ames, M. M., High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison, N Engl J Med, 1985. 312: p. 137-41., https://www.ncbi.nlm.nih.gov/pubmed/3880867

537. Chabot, J. A., Tsai, W. Y., Fine, R. L., Chen, C., Kumah, C. K., Antman, K. A., et.al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer, J Clin Oncol, 2010. 28: p. 2058-63., https://www.ncbi.nlm.nih.gov/pubmed/19687327

538. Buiatti, E., Arniani, S., Verdecchia, A., Tomatis, L., Results from a historical survey of the survival of cancer patients given Di Bella multitherapy, Cancer, 1999. 86: p. 2143-9., https://www.ncbi.nlm.nih.gov/pubmed/10570444

539. Milazzo, S., Lejeune, S., Ernst, E., Laetrile for cancer: a systematic review of the clinical evidence, Support Care Cancer, 2007. 15: p. 583-95., https://www.ncbi.nlm.nih.gov/pubmed/17106659

540. Ward, A. J., Dixon, B., Carcinoma of the cervix: results of a hyperbaric oxygen trial associated with the use of the cathetron, Clin Radiol, 1979. 30: p. 383-7., https://www.ncbi.nlm.nih.gov/pubmed/111890

541. Grossarth-Maticek, R., Ziegler, R., Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador), Forsch Komplementmed, 2007. 14: p. 140-7., https://www.ncbi.nlm.nih.gov/pubmed/17596694

542. Melzer, J., Iten, F., Hostanska, K., Saller, R., Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review, Forsch Komplementmed, 2009. 16: p. 217-26., https://www.ncbi.nlm.nih.gov/pubmed/19729932

543. Dale, P. S., Tamhankar, C. P., George, D., Daftary, G. V., Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects, Cancer Chemother Pharmacol, 2001. 47 Suppl: p. S29-34., https://www.ncbi.nlm.nih.gov/pubmed/11561869

544. Kumar, K. S., Srinivasan, V., Toles, R., Jobe, L., Seed, T. M., Nutritional approaches to radioprotection: vitamin E, Mil Med, 2002. 167: p. 57-9., https://www.ncbi.nlm.nih.gov/pubmed/11873518

545. Prasad, K. N., Cole, W. C., Kumar, B., Che Prasad, K., Pros and cons of antioxidant use during radiation therapy, Cancer Treat Rev, 2002. 28: p. 79-91., https://www.ncbi.nlm.nih.gov/pubmed/12297116

546. Ismail, M. S., Amer, A. S., Wahba, O., Shalby, H., Arian, F., Effect of antioxidants on markers of apoptosis in postoperative radiotherapy of cancer cervix, Gulf J Oncolog, 2010. p. 8-13., https://www.ncbi.nlm.nih.gov/pubmed/20164003

547. Vollbracht, C., Schneider, B., Leendert, V., Weiss, G., Auerbach, L., Beuth, J., Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany, In Vivo, 2011. 25: p. 983-90., https://www.ncbi.nlm.nih.gov/pubmed/22021693

548. Halperin, E. C., Gaspar, L., George, S., Darr, D., Pinnell, S., A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium, Int J Radiat Oncol Biol Phys, 1993. 26: p. 413-6., https://www.ncbi.nlm.nih.gov/pubmed/8514538

549. Muecke, R., Schomburg, L., Glatzel, M., Berndt-Skorka, R., Baaske, D., Reichl, B., et.al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology, Int J Radiat Oncol Biol Phys, 2010. 78: p. 828-35., https://www.ncbi.nlm.nih.gov/pubmed/20133068

550. Dennert, G., Zwahlen, M., Brinkman, M., Vinceti, M., Zeegers, M. P., Horneber, M., Selenium for preventing cancer, Cochrane Database Syst Rev, 2011. p. CD005195., https://www.ncbi.nlm.nih.gov/pubmed/29376219

551. Kucera, H., Micksche, M., Immunstimulation durch Vitamin A beim fortgeschrittenen Gebärmutterhals-Karzinom.pdf, Fortschr Med, 1982.

552. Kucera, H., Adjuvanticity of vitamin A in advanced irradiated cervical cancer (author's transl), Wien Klin Wochenschr Suppl, 1980. 118: p. 1-20., https://www.ncbi.nlm.nih.gov/pubmed/6162280

553. Hoffmann, W., Schiller, U., Rodemann, H. P., Bamberg, M., Vitamin A in tumor therapy: significance of clinical and pre-clinical findings for radiologic oncology Vitamin A in der Tumortherapie Zur Bedeutung klinischer und präklinischer Befunde für die Radioonkologie, Strahlenther Onkol, 1995. 171: p. 106-12.

554. Abu, J., Batuwangala, M., Herbert, K., Symonds, P., Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer, Lancet Oncol, 2005. 6: p. 712-20., https://www.ncbi.nlm.nih.gov/pubmed/16129372

555. Kim, H. S., Sardi, J. E., Katsumata, N., Ryu, H. S., Nam, J. H., Chung, H. H., et.al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis, Eur J Surg Oncol, 2013. 39: p. 115-24., https://www.ncbi.nlm.nih.gov/pubmed/23084091

556. Lutgendorf, S. K., Mullen-Houser, E., Russell, D., Degeest, K., Jacobson, G., Hart, L., et.al. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach, Brain Behav Immun, 2010. 24: p. 1231-40., https://www.ncbi.nlm.nih.gov/pubmed/20600809

557. Xu, M., Deng, P. X., Qi, C., Deng, B., Zhao, Z. Z., Wong, V., et.al. Adjuvant phytotherapy in the treatment of cervical cancer: a systematic review and meta-analysis, J Altern Complement Med, 2009. 15: p. 1347-53., https://www.ncbi.nlm.nih.gov/pubmed/19954338

558. Sreekanth, C. N., Bava, S. V., Sreekumar, E., Anto, R. J., Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer, Oncogene, 2011. 30: p. 3139-52., https://www.ncbi.nlm.nih.gov/pubmed/21317920

559. Maher, D. M., Bell, M. C., O'Donnell, E. A., Gupta, B. K., Jaggi, M., Chauhan, S. C., Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo(a)pyrene-induced upregulation of HPV E7, Mol Carcinog, 2011. 50: p. 47-57., https://www.ncbi.nlm.nih.gov/pubmed/21061268

560. Singh, M., Singh, N., Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells, Mol Cell Biochem, 2011. 347: p. 1-11., https://www.ncbi.nlm.nih.gov/pubmed/20941532

561. Yang, Z. G., Sun, H. X., Ye, Y. P., Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis, Chem Biodivers, 2006. 3: p. 187-97., https://www.ncbi.nlm.nih.gov/pubmed/17193257

562. Yalcin, F. N., Piacente, S., Perrone, A., Capasso, A., Duman, H., Calis, I., Cycloartane glycosides from Astragalus stereocalyx Bornm, Phytochemistry, 2012. 73: p. 119-26., https://www.ncbi.nlm.nih.gov/pubmed/22033014

563. Shin, J. I., Shim, J. H., Kim, K. H., Choi, H. S., Kim, J. W., Lee, H. G., et.al. Sensitization of the apoptotic effect of gamma-irradiation in genistein-pretreated CaSki cervical cancer cells, J Microbiol Biotechnol, 2008. 18: p. 523-31., https://www.ncbi.nlm.nih.gov/pubmed/18388472

564. Ahn, W. S., Kim, D. J., Chae, G. T., Lee, J. M., Bae, S. M., Sin, J. I., et.al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy, Int J Gynecol Cancer, 2004. 14: p. 589-94., https://www.ncbi.nlm.nih.gov/pubmed/15304151

565. Riyasdeen, A., Periasamy, V. S., Paul, P., Alshatwi, A. A., Akbarsha, M. A., Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers, Evid Based Complement Alternat Med, 2012. 2012: p. 136527., https://www.ncbi.nlm.nih.gov/pubmed/22114617

566. Linn, Y. H., Thu, K. K., Win, N. H. H., Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study, Probiotics Antimicrob Proteins, 2019. 11(2): p. 638-647., https://www.ncbi.nlm.nih.gov/pubmed/29550911

567. Gungorduk, K., Ozdemir, I. A., Gungorduk, O., Gulseren, V., Gokcu, M., Sanci, M., Effects of coffee consumption on gut recovery after surgery of gynecological cancer patients: a randomized controlled trial, Am J Obstet Gynecol, 2017. 216(2): p. 145 e1-145 e7., https://www.ncbi.nlm.nih.gov/pubmed/27780709

568. Duijts, S. F., Faber, M. M., Oldenburg, H. S., van Beurden, M., Aaronson, N. K., Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis, Psychooncology, 2011. 20(2): p. 115-26.

569. Reuss-Borst, M. A., Wentrock, S., Innovative individualized rehabilitation concepts in oncology, Dtsch Med Wochenschr, 2013. 138(17): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/23592347

570. Courneya, K. S., Exercise in cancer survivors: an overview of research, Med Sci Sports Exerc, 2003. 35(11): p. 1846-52.

571. Friendenreich, C. M., Courneya, K. S., Exercise as rehabilitation for cancer patients, Clin J Sport Med, 1996. 6(4): p. 237-44.

572. Oldervoll, L. M., Kaasa, S., Hjermstad, M. J., Lund, J. A., Loge, J. H., Physical exercise results in the improved subjective well-being of a few or is effective rehabilitation for all cancer patients?, Eur J Cancer, 2004. 40(7): p. 951-62.

573. Pinto, B. M., Maruyama, N. C., Exercise in the rehabilitation of breast cancer survivors, Psychooncology, 1999. 8(3): p. 191-206.

574. Stricker, C. T., Drake, D., Hoyer, K. A., Mock, V., Evidence-based practice for fatigue management in adults with cancer: exercise as an intervention, Oncol Nurs Forum, 2004. 31(5): p. 963-76.

575. Goodwin, J. S., Satish, S., Anderson, E. T., Nattinger, A. B., Freeman, J. L., Effect of nurse case management on the treatment of older women with breast cancer, J Am Geriatr Soc, 2003. 51(9): p. 1252-9.

576. Maunsell, E., Brisson, J., Deschenes, L., Frasure-Smith, N., Randomized trial of a psychologic distress screening program after breast cancer: effects on quality of life, J Clin Oncol, 1996. 14(10): p. 2747-55.

577. McArdle, J. M., George, W. D., McArdle, C. S., Smith, D. C., Moodie, A. R., Hughson, A. V., et.al. Psychological support for patients undergoing breast cancer surgery: a randomised study, Bmj, 1996. 312(7034): p. 813-6.

578. Rustoen, T., Begnum, S., Quality of life in women with breast cancer: a review of the literature and implications for nursing practice, Cancer Nurs, 2000. 23(6): p. 416-21.

579. Watson, Maggie, Denton, Sylvia, Baum, Michael, Greer, Steven, Counselling breast cancer patients: A specialist nurse service, Counselling Psychology Quarterly, 2007. 1(1): p. 25-34.

580. Andersen, L., Hojris, I., Erlandsen, M., Andersen, J., Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage--a randomized study, Acta Oncol, 2000. 39(3): p. 399-405.

581. McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., Hanson, J., The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial, Breast Cancer Res Treat, 2004. 86(2): p. 95-106.

582. Box, R. C., Reul-Hirche, H. M., Bullock-Saxton, J. E., Furnival, C. M., Physiotherapy after breast cancer surgery: results of a randomised controlled study to minimise lymphoedema, Breast Cancer Res Treat, 2002. 75(1): p. 51-64.

583. Playdon, M., Thomas, G., Sanft, T., Harrigan, M., Ligibel, J., Irwin, M., Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review, Curr Breast Cancer Rep, 2013. 5(3): p. 222-246., https://www.ncbi.nlm.nih.gov/pubmed/26605003

584. Luebbert, K., Dahme, B., Hasenbring, M., The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review, Psychooncology, 2001. 10(6): p. 490-502.

585. Devine, E. C., Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer, Oncol Nurs Forum, 2003. 30(1): p. 75-89.

586. Van Kuiken, D., A meta-analysis of the effect of guided imagery practice on outcomes, J Holist Nurs, 2004. 22(2): p. 164-79.

587. Edwards, Adrian, Hailey, S., Maxwell, M., Psychological interventions for women with metastatic breast cancer (Cochrane Review), Cochrane database of systematic reviews (Online), 2004. 2: p. CD004253.

588. Spiegel, D., Bloom, J. R., Kraemer, H. C., Gottheil, E., Effect of psychosocial treatment on survival of patients with metastatic breast cancer, Lancet, 1989. 2(8668): p. 888-91.

589. S, Burke, DW, Kissane, Psychosocial impact of breast cancer: a review of interventions by specialist providers: a summary of the literature 1976-1996, 1998.

590. Chow, E., Tsao, M. N., Harth, T., Does psychosocial intervention improve survival in cancer? A meta-analysis, Palliat Med, 2004. 18(1): p. 25-31.

591. Meyer, T. J., Mark, M. M., Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments, Health Psychol, 1995. 14(2): p. 101-8.

592. Bourbonniere, M., Kagan, S. H., Nursing intervention and older adults who have cancer: specific science and evidence based practice, Nurs Clin North Am, 2004. 39(3): p. 529-43.

593. Edgar, L., Rosberger, Z., Nowlis, D., Coping with cancer during the first year after diagnosis. Assessment and intervention, Cancer, 1992. 69(3): p. 817-28.

594. Zibecchi, L., Greendale, G. A., Ganz, P. A., Continuing education: Comprehensive menopausal assessment: an approach to managing vasomotor and urogenital symptoms in breast cancer survivors, Oncol Nurs Forum, 2003. 30(3): p. 393-407.

595. Allen, S. M., Shah, A. C., Nezu, A. M., Nezu, C. M., Ciambrone, D., Hogan, J., et.al. A problem-solving approach to stress reduction among younger women with breast carcinoma: a randomized controlled trial, Cancer, 2002. 94(12): p. 3089-100.

596. Badger, T. A., Braden, C. J., Mishel, M. H., Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer, Oncol Nurs Forum, 2001. 28(3): p. 567-74.

597. Fawzy, F. I., Fawzy, N. W., Arndt, L. A., Pasnau, R. O., Critical review of psychosocial interventions in cancer care, Arch Gen Psychiatry, 1995. 52(2): p. 100-13.

598. Sellick, S. M., Crooks, D. L., Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions, Psychooncology, 1999. 8(4): p. 315-33.

599. Arathuzik, D., Effects of cognitive-behavioral strategies on pain in cancer patients, Cancer Nurs, 1994. 17(3): p. 207-14.

600. D, Kissane, S, Burke, Psychosocial support for breast cancer patients provided by members of the treatment team: A summary of the literature, 1976-1996. NHMRC National Breast Cancer Centre, 1998.

601. Choi, H., Palmer, M. H., Park, J., Meta-analysis of pelvic floor muscle training: randomized controlled trials in incontinent women, Nurs Res, 2007. 56(4): p. 226-34., http://www.ncbi.nlm.nih.gov/pubmed/17625461

602. Dumoulin, C., Hay-Smith, J., Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women, Cochrane Database Syst Rev, 2010. p. CD005654., https://www.ncbi.nlm.nih.gov/pubmed/24823491

603. Hosker, G., Cody, J. D., Norton, C. C., Electrical stimulation for faecal incontinence in adults, Cochrane Database Syst Rev, 2007. p. CD001310., https://www.ncbi.nlm.nih.gov/pubmed/10796769

604. Imamura, M., Abrams, P., Bain, C., Buckley, B., Cardozo, L., Cody, J., et.al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence, Health Technol Assess, 2010. 14: p. 1-188, iii-iv., https://www.ncbi.nlm.nih.gov/pubmed/20738930

605. Norton, C., Cody, J. D., Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults, Cochrane Database Syst Rev, 2012. 7: p. CD002111., https://www.ncbi.nlm.nih.gov/pubmed/22786479

606. Salvo, G., Gonzalez Martin, A., Gonzales, N. R., Frumovitz, M., Updates and management algorithm for neuroendocrine tumors of the uterine cervix, Int J Gynecol Cancer, 2019. 29(6): p. 986-995., https://www.ncbi.nlm.nih.gov/pubmed/31263021

607. Patil SP, Nagrale AV, SD, Ganvir, Additive effect of interferential therapy over pelvic floor exercises, International Journal of Therapy & Rehabilitation, 2010. 17: p. 596-602.

608. Hartmann, K. E., McPheeters, M. L., Biller, D. H., Ward, R. M., McKoy, J. N., Jerome, R. N., et.al. Treatment of overactive bladder in women, Evid Rep Technol Assess (Full Rep), 2009. p. 1-120, v., https://www.ncbi.nlm.nih.gov/pubmed/19947666

609. Berghmans, B., van Waalwijk van Doorn, E., Nieman, F., de Bie, R., van den Brandt, P., Van Kerrebroeck, P., Efficacy of physical therapeutic modalities in women with proven bladder overactivity, Eur Urol, 2002. 41: p. 581-7., https://www.ncbi.nlm.nih.gov/pubmed/12074773

610. Wang, A. C., Wang, Y. Y., Chen, M. C., Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder, Urology, 2004. 63: p. 61-6., https://www.ncbi.nlm.nih.gov/pubmed/14751349

611. Shamliyan, T. A., Kane, R. L., Wyman, J., Wilt, T. J., Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women, Ann Intern Med, 2008. 148: p. 459-73., https://www.ncbi.nlm.nih.gov/pubmed/18268288

612. Theofrastous, J. P., Wyman, J. F., Bump, R. C., McClish, D. K., Elser, D. M., Bland, D. R., et.al. Effects of pelvic floor muscle training on strength and predictors of response in the treatment of urinary incontinence, Neurourol Urodyn, 2002. 21: p. 486-90., https://www.ncbi.nlm.nih.gov/pubmed/12232886

613. S2k_Diagnostik_und_Therapie_der_Lymphoedeme AWMF Reg.-Nr. 058-001, 2017., https://www.awmf.org/uploads/tx_szleitlinien/058-001l_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2019-07.pdf

614. Velthuis, M. J., Agasi-Idenburg, S. C., Aufdemkampe, G., Wittink, H. M., The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials, Clin Oncol (R Coll Radiol), 2010. 22: p. 208-21., https://www.ncbi.nlm.nih.gov/pubmed/20110159

615. Cramp, F., Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2008. p. CD006145., https://www.ncbi.nlm.nih.gov/pubmed/23152233

616. Brown, J. C., Huedo-Medina, T. B., Pescatello, L. S., Pescatello, S. M., Ferrer, R. A., Johnson, B. T., Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 2011. 20: p. 123-33., https://www.ncbi.nlm.nih.gov/pubmed/21051654

617. Adamsen, L., Quist, M., Andersen, C., Moller, T., Herrstedt, J., Kronborg, D., et.al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial, BMJ, 2009. 339: p. b3410., https://www.ncbi.nlm.nih.gov/pubmed/19826172

618. Bourke, L., Thompson, G., Gibson, D. J., Daley, A., Crank, H., Adam, I., et.al. Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study, Arch Phys Med Rehabil, 2011. 92: p. 749-55., https://www.ncbi.nlm.nih.gov/pubmed/21530722

619. Cantarero-Villanueva, I., Fernandez-Lao, C., Del Moral-Avila, R., Fernandez-de-Las-Penas, C., Feriche-Fernandez-Castanys, M. B., Arroyo-Morales, M., Effectiveness of core stability exercises and recovery myofascial release massage on fatigue in breast cancer survivors: a randomized controlled clinical trial, Evid Based Complement Alternat Med, 2012. 2012: p. 620619., https://www.ncbi.nlm.nih.gov/pubmed/21792370

620. Courneya, K. S., Segal, R. J., Reid, R. D., Jones, L. W., Malone, S. C., Venner, P. M., et.al. Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors, J Clin Epidemiol, 2004. 57: p. 571-9., https://www.ncbi.nlm.nih.gov/pubmed/15246125

621. Danhauer, S. C., Mihalko, S. L., Russell, G. B., Campbell, C. R., Felder, L., Daley, K., et.al. Restorative yoga for women with breast cancer: findings from a randomized pilot study, Psychooncology, 2009. 18: p. 360-8., https://www.ncbi.nlm.nih.gov/pubmed/19242916

622. Fillion, L., Gagnon, P., Leblond, F., Gelinas, C., Savard, J., Dupuis, R., et.al. A brief intervention for fatigue management in breast cancer survivors, Cancer Nurs, 2008. 31: p. 145-59., https://www.ncbi.nlm.nih.gov/pubmed/18490891

623. Heim, M. E., v d Malsburg, M. L., Niklas, A., Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue, Onkologie, 2007. 30: p. 429-34., https://www.ncbi.nlm.nih.gov/pubmed/17848814

624. Littman, A. J., Bertram, L. C., Ceballos, R., Ulrich, C. M., Ramaprasad, J., McGregor, B., et.al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures, Support Care Cancer, 2012. 20: p. 267-77., https://www.ncbi.nlm.nih.gov/pubmed/21207071

625. Moadel, A. B., Shah, C., Wylie-Rosett, J., Harris, M. S., Patel, S. R., Hall, C. B., et.al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life, J Clin Oncol, 2007. 25: p. 4387-95., https://www.ncbi.nlm.nih.gov/pubmed/17785709

626. Pinto, B. M., Rabin, C., Papandonatos, G. D., Frierson, G. M., Trunzo, J. J., Marcus, B. H., Maintenance of effects of a home-based physical activity program among breast cancer survivors, Support Care Cancer, 2008. 16: p. 1279-89., https://www.ncbi.nlm.nih.gov/pubmed/18414905

627. Heim, M. E., v d Malsburg, M. L., Niklas, A., Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue, Onkologie, 2007. 30(8-9): p. 429-34., http://www.ncbi.nlm.nih.gov/pubmed/17848814

628. Liebig, C., Ayala, G., Wilks, J. A., Berger, D. H., Albo, D., Perineural invasion in cancer: a review of the literature, Cancer, 2009. 115: p. 3379-91., https://www.ncbi.nlm.nih.gov/pubmed/19484787

629. Rogers, L. Q., Hopkins-Price, P., Vicari, S., Markwell, S., Pamenter, R., Courneya, K. S., et.al. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects, Cancer Epidemiol Biomarkers Prev, 2009. 18: p. 1410-8., https://www.ncbi.nlm.nih.gov/pubmed/19383889

630. van Weert, E., May, A. M., Korstjens, I., Post, W. J., van der Schans, C. P., van den Borne, B., et.al. Cancer-related fatigue and rehabilitation: a randomized controlled multicenter trial comparing physical training combined with cognitive-behavioral therapy with physical training only and with no intervention, Phys Ther, 2010. 90: p. 1413-25., https://www.ncbi.nlm.nih.gov/pubmed/20651011

631. Chandwani, K. D., Thornton, B., Perkins, G. H., Arun, B., Raghuram, N. V., Nagendra, H. R., et.al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer, J Soc Integr Oncol, 2010. 8: p. 43-55., https://www.ncbi.nlm.nih.gov/pubmed/20388445

632. Mustian, K. M., Peppone, L., Darling, T. V., Palesh, O., Heckler, C. E., Morrow, G. R., A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial, J Support Oncol, 2009. 7: p. 158-67., https://www.ncbi.nlm.nih.gov/pubmed/19831159

633. Donnelly, C. M., Blaney, J. M., Lowe-Strong, A., Rankin, J. P., Campbell, A., McCrum-Gardner, E., et.al. A randomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors, Gynecol Oncol, 2011. 122: p. 618-24., https://www.ncbi.nlm.nih.gov/pubmed/21689848

634. Ebede, C. C., Jang, Y., Escalante, C. P., Cancer-Related Fatigue in Cancer Survivorship, Med Clin North Am, 2017. 101(6): p. 1085-1097., https://www.ncbi.nlm.nih.gov/pubmed/28992856

635. Mohandas, H., Jaganathan, S. K., Mani, M. P., Ayyar, M., Rohini Thevi, G. V., Cancer-related fatigue treatment: An overview, J Cancer Res Ther, 2017. 13(6): p. 916-929., https://www.ncbi.nlm.nih.gov/pubmed/29237952

636. Bower, J. E., Cancer-related fatigue--mechanisms, risk factors, and treatments, Nat Rev Clin Oncol, 2014. 11(10): p. 597-609., https://www.ncbi.nlm.nih.gov/pubmed/25113839

637. Frumovitz, M., Sun, C. C., Schover, L. R., Munsell, M. F., Jhingran, A., Wharton, J. T., et.al. Quality of life and sexual functioning in cervical cancer survivors, J Clin Oncol, 2005. 23: p. 7428-36., https://www.ncbi.nlm.nih.gov/pubmed/16234510

638. Wilmoth, M. C., Botchway, P., Psychosexual implications of breast and gynecologic cancer, Cancer Invest, 1999. 17: p. 631-6., https://www.ncbi.nlm.nih.gov/pubmed/10592769

639. Juraskova, I., Butow, P., Robertson, R., Sharpe, L., McLeod, C., Hacker, N., Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight, Psychooncology, 2003. 12: p. 267-79., https://www.ncbi.nlm.nih.gov/pubmed/12673810

640. Andersen, B. L., Woods, X. A., Copeland, L. J., Sexual self-schema and sexual morbidity among gynecologic cancer survivors, J Consult Clin Psychol, 1997. 65: p. 221-9., https://www.ncbi.nlm.nih.gov/pubmed/9086685

641. Flynn, Paul, Kew, Fiona, Kisely Steve, R., Interventions for psychosexual dysfunction in women treated for gynaecological malignancyJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2009., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513649/

642. Brotto, L. A., Heiman, J. R., Goff, B., Greer, B., Lentz, G. M., Swisher, E., et.al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer, Arch Sex Behav, 2008. 37: p. 317-29., https://www.ncbi.nlm.nih.gov/pubmed/17680353

643. Amsterdam, A., Krychman, M. L., Sexual dysfunction in patients with gynecologic neoplasms: a retrospective pilot study, J Sex Med, 2006. 3: p. 646-9., https://www.ncbi.nlm.nih.gov/pubmed/16776780

644. Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., et.al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, J Clin Oncol, 2006. 24: p. 5091-7., https://www.ncbi.nlm.nih.gov/pubmed/17033037

645. Grunfeld, E., Dhesy-Thind, S., Levine, M., Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update), CMAJ, 2005. 172: p. 1319-20., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC557103/

646. Pestalozzi, B. C., Luporsi-Gely, E., Jost, L. M., Bergh, J., ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer, Ann Oncol, 2005. 16 Suppl 1: p. i7-9., https://www.ncbi.nlm.nih.gov/pubmed/15888763

647. Hurria, A., Hudis, C., Follow-up care of breast cancer survivors, Crit Rev Oncol Hematol, 2003. 48: p. 89-99., https://www.ncbi.nlm.nih.gov/pubmed/14585486

648. Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., et.al. Follow-up strategies for women treated for early breast cancer, Cochrane Database Syst Rev, 2005. p. CD001768., https://www.ncbi.nlm.nih.gov/pubmed/15674884

649. Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del Turco, M., Distante, V., et.al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up, JAMA, 1999. 281: p. 1586., https://www.ncbi.nlm.nih.gov/pubmed/10235147

650. Gulliford, T., Opomu, M., Wilson, E., Hanham, I., Epstein, R., Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study, BMJ, 1997. 314: p. 174-7., https://www.ncbi.nlm.nih.gov/pubmed/9022429

651. Elit, L., Fyles, A. W., Devries, M. C., Oliver, T. K., Fung-Kee-Fung, M., Gynecology Cancer Disease Site, Group, Follow-up for women after treatment for cervical cancer: a systematic review, Gynecol Oncol, 2009. 114: p. 528-35., https://www.ncbi.nlm.nih.gov/pubmed/19560188

652. Selby, P., Gillis, C., Haward, R., Benefits from specialised cancer care, Lancet, 1996. 348: p. 313-8., https://www.ncbi.nlm.nih.gov/pubmed/8709693

653. Hillesheim, I., Limone, G. A., Klimann, L., Monego, H., Appel, M., de Souza, A., et.al. Cervical Cancer Posttreatment Follow-up: Critical Analysis, Int J Gynecol Cancer, 2017. 27(8): p. 1747-1752., https://www.ncbi.nlm.nih.gov/pubmed/28937445

654. Lanceley, A., Fiander, A., McCormack, M., Bryant, A., Follow-up protocols for women with cervical cancer after primary treatment, Cochrane Database Syst Rev, 2013. 11: p. Cd008767., https://www.ncbi.nlm.nih.gov/pubmed/24277645

655. Rimel, B. J., Ferda, A., Erwin, J., Dewdney, S. B., Seamon, L., Gao, F., et.al. Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment, Obstet Gynecol, 2011. 118: p. 548-53., https://www.ncbi.nlm.nih.gov/pubmed/21860282

656. Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., Colombo, N., et.al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2017. 28(suppl_4): p. iv72-iv83., https://www.ncbi.nlm.nih.gov/pubmed/28881916

657. Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., Colombo, N., et.al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(Suppl 4): p. iv262., https://www.ncbi.nlm.nih.gov/pubmed/29741577

658. Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J., Poljak, M., Ogilvie, G., et.al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, 2012. 30 Suppl 5: p. F88-99., https://www.ncbi.nlm.nih.gov/pubmed/23199969

659. Edey, K., Denton, K., Murdoch, J., The role of cytological follow-up after radical vaginal trachelectomy for early-stage cervical cancer, Cytopathology, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23802711

660. Sturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaarenstroom, K., et.al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers, Clin Chem, 2010. 56: p. e1-48., https://www.ncbi.nlm.nih.gov/pubmed/20207771

661. Wong, T. Z., Jones, E. L., Coleman, R. E., Positron emission tomography with 2-deoxy-2-((18)F)fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer, Mol Imaging Biol, 2004. 6: p. 55-62., https://www.ncbi.nlm.nih.gov/pubmed/15018829

662. Mirpour, S., Mhlanga, J. C., Logeswaran, P., Russo, G., Mercier, G., Subramaniam, R. M., The role of PET/CT in the management of cervical cancer, AJR Am J Roentgenol, 2013. 201: p. W192-205., https://www.ncbi.nlm.nih.gov/pubmed/23883234

663. Fyles, A., Walker-Dilks, C., PET Imaging in Cervical Cancer, Cancer Care Ontario, 2009.

664. Zhou, Z., Liu, X., Hu, K., Zhang, F., The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence, Nucl Med Commun, 2018. 39(2): p. 97-102., https://www.ncbi.nlm.nih.gov/pubmed/29189444

665. Brito, A. E. T., Matushita, C., Esteves, F., Gomes, G., Bernardo, W. M., Amorim, B. J., Cervical cancer - staging and restaging with 18F-FDG PET/CT, Rev Assoc Med Bras (1992), 2019. 65(4): p. 568-575., https://www.ncbi.nlm.nih.gov/pubmed/31066810

666. Viswanathan, C., Faria, S., Devine, C., Patnana, M., Sagebiel, T., Iyer, R. B., et.al. [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer, PET Clin, 2018. 13(2): p. 165-177., https://www.ncbi.nlm.nih.gov/pubmed/29482748

668. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., et.al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging, J Clin Oncol, 2013. 31: p. 3026-33., https://www.ncbi.nlm.nih.gov/pubmed/23857967

669. Beier, D, HPV-Impfung - Mitteilung der Sächsischen Impfkommissiom, Ärzteblatt Sachsen, 2011. 1:

670. Munoz, N., Manalastas, R., Jr., Pitisuttithum, P., Tresukosol, D., Monsonego, J., Ault, K., et.al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial, Lancet, 2009. 373: p. 1949-57., https://www.ncbi.nlm.nih.gov/pubmed/19493565

671. Olsson, S. E., Kjaer, S. K., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Wheeler, C. M., et.al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Hum Vaccin, 2009. 5: p. 696-704., https://www.ncbi.nlm.nih.gov/pubmed/19855170

672. Hampl, M., Value of general human papillomavirus vaccination in sexually active women, Dtsch Med Wochenschr, 2009. 134 Suppl 2: p. S95-9., https://www.ncbi.nlm.nih.gov/pubmed/19353480

673. Schwarz, T. F., Spaczynski, M., Schneider, A., Wysocki, J., Galaj, A., Perona, P., et.al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years, Vaccine, 2009. 27: p. 581-7., https://www.ncbi.nlm.nih.gov/pubmed/19022320

674. Castellsague, X., Schneider, A., Kaufmann, A. M., Bosch, F. X., HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives, Gynecol Oncol, 2009. 115: p. S15-23., https://www.ncbi.nlm.nih.gov/pubmed/19819540

675. Mundt, A. J., Mell, L. K., Roeske, J. C., Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy, Int J Radiat Oncol Biol Phys, 2003. 56: p. 1354-60., https://www.ncbi.nlm.nih.gov/pubmed/12873680

676. Shimada, M., Kigawa, J., Nishimura, R., Yamaguchi, S., Kuzuya, K., Nakanishi, T., et.al. Ovarian metastasis in carcinoma of the uterine cervix, Gynecol Oncol, 2006. 101(2): p. 234-7., https://www.ncbi.nlm.nih.gov/pubmed/16300819

677. Joura, E. A., Garland, S. M., Paavonen, J., Ferris, D. G., Perez, G., Ault, K. A., et.al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data, BMJ, 2012. 344: p. e1401., https://www.ncbi.nlm.nih.gov/pubmed/22454089

678. Kang, W. D., Choi, H. S., Kim, S. M., Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?, Gynecol Oncol, 2013. 130(2): p. 264-8., https://www.ncbi.nlm.nih.gov/pubmed/23623831

679. Monsonego, J., Cortes, J., Greppe, C., Hampl, M., Joura, E., Singer, A., Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine, Vaccine, 2010. 28: p. 8065-72., https://www.ncbi.nlm.nih.gov/pubmed/20971114

680. STIKO, STIKO-Impfkalender 2011, 2011.

681. Koch-Institut, Robert, Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2011, Epid Bulletin, 2011. 30: p. 275–94.

682. Kamura, T., Tsukamoto, N., Tsuruchi, N., Saito, T., Matsuyama, T., Akazawa, K., et.al. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy, Cancer, 1992. 69(1): p. 181-6., https://www.ncbi.nlm.nih.gov/pubmed/1727662

683. Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J., Poljak, M., Ogilvie, G., et.al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, 2012. 30 Suppl 5: p. F88-99., http://www.ncbi.nlm.nih.gov/pubmed/23199969

684. Wang, C. J., Lai, C. H., Huang, H. J., Hong, J. H., Chou, H. H., Huang, K. G., et.al. Recurrent cervical carcinoma after primary radical surgery, Am J Obstet Gynecol, 1999. 181(3): p. 518-24., https://www.ncbi.nlm.nih.gov/pubmed/10486457

685. Perez, C. A., Fox, S., Lockett, M. A., Grigsby, P. W., Camel, H. M., Galakatos, A., et.al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods, Int J Radiat Oncol Biol Phys, 1991. 21: p. 885-98., https://www.ncbi.nlm.nih.gov/pubmed/1917616

686. Fagundes, H., Perez, C. A., Grigsby, P. W., Lockett, M. A., Distant metastases after irradiation alone in carcinoma of the uterine cervix, Int J Radiat Oncol Biol Phys, 1992. 24: p. 197-204., https://www.ncbi.nlm.nih.gov/pubmed/1526855

687. van Nagell, J. R., Jr., Rayburn, W., Donaldson, E. S., Hanson, M., Gay, E. C., Yoneda, J., et.al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix, Cancer, 1979. 44: p. 2354-61., https://www.ncbi.nlm.nih.gov/pubmed/116764

688. Hong, J. H., Tsai, C. S., Lai, C. H., Chang, T. C., Wang, C. C., Chou, H. H., et.al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 60: p. 249-57., https://www.ncbi.nlm.nih.gov/pubmed/15337563

689. McLean, K. A., Zhang, W., Dunsmoor-Su, R. F., Shah, C. A., Gray, H. J., Swensen, R. E., et.al. Pelvic exenteration in the age of modern chemoradiation, Gynecol Oncol, 2011. 121: p. 131-4., https://www.ncbi.nlm.nih.gov/pubmed/21256580

690. Bodurka-Bevers, D., Morris, M., Eifel, P. J., Levenback, C., Bevers, M. W., Lucas, K. R., et.al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis, Gynecol Oncol, 2000. 78: p. 187-93., https://www.ncbi.nlm.nih.gov/pubmed/10926801

691. Wen, H., Wu, X., Li, Z., Wang, H., Zang, R., Sun, M., et.al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer, Int J Gynecol Cancer, 2012. 22(2): p. 296-302., http://www.ncbi.nlm.nih.gov/pubmed/22274319

692. James, R. M., Cruickshank, M. E., Siddiqui, N., Guideline Development, Group, Management of cervical cancer: summary of SIGN guidelines, BMJ, 2008. 336(7634): p. 41-3., https://www.ncbi.nlm.nih.gov/pubmed/18174599

693. Paunier, J. P., Delclos, L., Fletcher, G. H., Causes, time of death, and sites of failure in squamous-cell carcinoma of the uterine cervix on intact uterus, Radiology, 1967. 88: p. 555-62., https://www.ncbi.nlm.nih.gov/pubmed/6019520

694. Noh, J. M., Park, W., Kim, Y. S., Kim, J. Y., Kim, H. J., Kim, J., et.al. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10), Gynecol Oncol, 2014. 132(3): p. 618-23., https://www.ncbi.nlm.nih.gov/pubmed/24486605

695. Ferreira, M. P., Coghill, A. E., Chaves, C. B., Bergmann, A., Thuler, L. C., Soares, E. A., et.al. Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer, AIDS, 2017. 31(4): p. 523-531., https://www.ncbi.nlm.nih.gov/pubmed/28060014

696. Maneo, A., Landoni, F., Cormio, G., Colombo, A., Placa, F., Pellegrino, A., et.al. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma, Ann Oncol, 1999. 10(7): p. 803-7., https://www.ncbi.nlm.nih.gov/pubmed/10470427

697. Peiretti, M., Zapardiel, I., Zanagnolo, V., Landoni, F., Morrow, C. P., Maggioni, A., Management of recurrent cervical cancer: a review of the literature, Surg Oncol, 2012. 21: p. e59-66., https://www.ncbi.nlm.nih.gov/pubmed/22244884

698. Ito, H., Shigematsu, N., Kawada, T., Kubo, A., Isobe, K., Hara, R., et.al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy, Gynecol Oncol, 1997. 67: p. 154-61., https://www.ncbi.nlm.nih.gov/pubmed/9367699

699. Kamura, T., Tsukamoto, N., Tsuruchi, N., Saito, T., Matsuyama, T., Akazawa, K., et.al. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy, Cancer, 1992. 69(1): p. 181-6., https://www.ncbi.nlm.nih.gov/pubmed/1727662

700. Jain, P., Hunter, R. D., Livsey, J. E., Coyle, C., Swindell, R., Davidson, S. E., Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer, Clin Oncol (R Coll Radiol), 2007. 19(10): p. 763-8., https://www.ncbi.nlm.nih.gov/pubmed/17931845

701. Ijaz, T., Eifel, P. J., Burke, T., Oswald, M. J., Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma, Gynecol Oncol, 1998. 70(2): p. 241-6., https://www.ncbi.nlm.nih.gov/pubmed/9740698

702. Berek, J. S., Howe, C., Lagasse, L. D., Hacker, N. F., Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA, Gynecol Oncol, 2005. 99(1): p. 153-9., https://www.ncbi.nlm.nih.gov/pubmed/16054678

703. Magrina, J. F., Stanhope, C. R., Weaver, A. L., Pelvic exenterations: supralevator, infralevator, and with vulvectomy, Gynecol Oncol, 1997. 64(1): p. 130-5., https://www.ncbi.nlm.nih.gov/pubmed/8995561

704. Perez, C. A., Fox, S., Lockett, M. A., Grigsby, P. W., Camel, H. M., Galakatos, A., et.al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods, Int J Radiat Oncol Biol Phys, 1991. 21(4): p. 885-98., https://www.ncbi.nlm.nih.gov/pubmed/1917616

705. van Nagell, J. R., Jr., Rayburn, W., Donaldson, E. S., Hanson, M., Gay, E. C., Yoneda, J., et.al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix, Cancer, 1979. 44(6): p. 2354-61., https://www.ncbi.nlm.nih.gov/pubmed/116764

706. Possover, M., Drahonowski, J., Plaul, K., Schneider, A., Laparoscopic-assisted formation of a colon neovagina, Surg Endosc, 2001. 15: p. 623., https://www.ncbi.nlm.nih.gov/pubmed/11591954

707. Lopez-Graniel, C., Dolores, R., Cetina, L., Gonzalez, A., Cantu, D., Chanona, J., et.al. Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer, BMC Cancer, 2005. 5: p. 118., https://www.ncbi.nlm.nih.gov/pubmed/16171526

708. Hockel, M., Laterally extended endopelvic resection (LEER)-principles and practice, Gynecol Oncol, 2008. 111: p. S13-7., https://www.ncbi.nlm.nih.gov/pubmed/18723213

709. Hong, J. H., Tsai, C. S., Lai, C. H., Chang, T. C., Wang, C. C., Chou, H. H., et.al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 60(1): p. 249-57., https://www.ncbi.nlm.nih.gov/pubmed/15337563

710. Yoo, H. J., Lim, M. C., Seo, S. S., Kang, S., Yoo, C. W., Kim, J. Y., et.al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea, J Gynecol Oncol, 2012. 23: p. 242-50., https://www.ncbi.nlm.nih.gov/pubmed/23094127

711. Marnitz, S., Kohler, C., Muller, M., Behrens, K., Hasenbein, K., Schneider, A., Indications for primary and secondary exenterations in patients with cervical cancer, Gynecol Oncol, 2006. 103: p. 1023-30., https://www.ncbi.nlm.nih.gov/pubmed/16890276

712. Forner, D. M., Lampe, B., Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors, Am J Obstet Gynecol, 2011. 205: p. 148 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/21640963

713. Schmidt, A. M., Imesch, P., Fink, D., Egger, H., Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer, Gynecol Oncol, 2012. 125: p. 604-9., https://www.ncbi.nlm.nih.gov/pubmed/22406639

714. Estape, R., Angioli, R., Surgical management of advanced and recurrent cervical cancer, Semin Surg Oncol, 1999. 16: p. 236-41., https://www.ncbi.nlm.nih.gov/pubmed/10225302

715. Wittekind, C, Meyer, HJ, TNM-Klassifikation maligner TumorenViley-VCH Verlag, 2010.

716. Coleman, R. L., Keeney, E. D., Freedman, R. S., Burke, T. W., Eifel, P. J., Rutledge, F. N., Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy, Gynecol Oncol, 1994. 55: p. 29-35., https://www.ncbi.nlm.nih.gov/pubmed/7959262

717. Mahe, M. A., Gerard, J. P., Dubois, J. B., Roussel, A., Bussieres, E., Delannes, M., et.al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients, Int J Radiat Oncol Biol Phys, 1996. 34: p. 21-6., https://www.ncbi.nlm.nih.gov/pubmed/12118553

718. Windschall, A., Ott, O. J., Sauer, R., Strnad, V., Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma, Strahlenther Onkol, 2005. 181: p. 545-50., https://www.ncbi.nlm.nih.gov/pubmed/16044224

719. Haasbeek, C. J., Uitterhoeve, A. L., van der Velden, J., Gonzalez, D. G., Stalpers, L. J., Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery, Radiother Oncol, 2008. 89: p. 197-204., https://www.ncbi.nlm.nih.gov/pubmed/18237803

720. Grigsby, P. W., Prospective phase I/II study of irradiation and concurrent chemotherapy for recurrent cervical cancer after radical hysterectomy, Int J Gynecol Cancer, 2004. 14: p. 860-4., https://www.ncbi.nlm.nih.gov/pubmed/15361195

721. Westermann, A., Mella, O., Van Der Zee, J., Jones, E. L., Van Der Steen-Banasik, E., Koper, P., et.al. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update, Int J Hyperthermia, 2012. 28: p. 549-53., https://www.ncbi.nlm.nih.gov/pubmed/22788973

722. Mundt, A. J., Roeske, J. C., Lujan, A. E., Yamada, S. D., Waggoner, S. E., Fleming, G., et.al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies, Gynecol Oncol, 2001. 82(3): p. 456-63., https://www.ncbi.nlm.nih.gov/pubmed/11520140

723. Liu, S. P., Huang, X., Ke, G. H., Huang, X. W., 3D radiation therapy or intensity-modulated radiotherapy for recurrent and metastatic cervical cancer: the Shanghai Cancer Hospital experience, PLoS One, 2012. 7(6): p. e40299., https://www.ncbi.nlm.nih.gov/pubmed/22768273

724. Blohmer, J. U., Paepke, S., Sehouli, J., Boehmer, D., Kolben, M., Wurschmidt, F., et.al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study, J Clin Oncol, 2011. 29(28): p. 3791-7., http://www.ncbi.nlm.nih.gov/pubmed/21860000, http://jco.ascopubs.org/content/29/28/3791.full.pdf

725. Fokdal, L., Sturdza, A., Mazeron, R., Haie-Meder, C., Tan, L. T., Gillham, C., et.al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study, Radiother Oncol, 2016. 120(3): p. 434-440., https://www.ncbi.nlm.nih.gov/pubmed/27113795

726. Seo, Y., Kim, M. S., Yoo, H. J., Jang, W. I., Rhu, S. Y., Choi, S. C., et.al. Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication, Asia Pac J Clin Oncol, 2016. 12(2): p. e280-8., https://www.ncbi.nlm.nih.gov/pubmed/24889550

727. Krengli, M., Pisani, C., Deantonio, L., Surico, D., Volpe, A., Surico, N., et.al. Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers, Radiat Oncol, 2017. 12(1): p. 18., https://www.ncbi.nlm.nih.gov/pubmed/28100242

728. Stelzer, K. J., Koh, W. J., Greer, B. E., Cain, J. M., Tamimi, H. K., Figge, D. C., et.al. The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity, Am J Obstet Gynecol, 1995. 172(6): p. 1881-6; discussion 1886-8., https://www.ncbi.nlm.nih.gov/pubmed/7778648

729. Hockel, M., Horn, L. C., Einenkel, J., (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy, Gynecol Oncol, 2012. 127: p. 297-302., https://www.ncbi.nlm.nih.gov/pubmed/22864112

730. Jurado, M., Alcazar, J. L., Martinez-Monge, R., Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience, Gynecol Oncol, 2010. 116(1): p. 38-43., https://www.ncbi.nlm.nih.gov/pubmed/19878978

731. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6: p. CD011129., https://www.ncbi.nlm.nih.gov/pubmed/28603881

732. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. [Integration of palliative care into intensive care : Systematic review], Anaesthesist, 2017. 66(9): p. 660-666., https://www.ncbi.nlm.nih.gov/pubmed/28589374

733. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., https://www.ncbi.nlm.nih.gov/pubmed/24621947

734. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., https://www.ncbi.nlm.nih.gov/pubmed/26231807

735. Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925., https://www.ncbi.nlm.nih.gov/pubmed/28676557

736. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826

737. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://www.ncbi.nlm.nih.gov/pubmed/26464077

738. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/27185614

739. Lee, S. Y., Lee, N. R., Cho, D. H., Kim, J. S., Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation, Oncol Lett, 2017. 14(1): p. 73-78., https://www.ncbi.nlm.nih.gov/pubmed/28693137

740. Orbegoso, C., Murali, K., Banerjee, S., The current status of immunotherapy for cervical cancer, Rep Pract Oncol Radiother, 2018. 23(6): p. 580-588., https://www.ncbi.nlm.nih.gov/pubmed/30534022

741. Frenel, J. S., Le Tourneau, C., O'Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., et.al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial, J Clin Oncol, 2017. 35(36): p. 4035-4041., https://www.ncbi.nlm.nih.gov/pubmed/29095678

742. Stevanovic, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., et.al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells, J Clin Oncol, 2015. 33(14): p. 1543-50., https://www.ncbi.nlm.nih.gov/pubmed/25823737

743. Bhatla, N., Aoki, D., Sharma, D. N., Sankaranarayanan, R., Cancer of the cervix uteri, Int J Gynaecol Obstet, 2018. 143 Suppl 2: p. 22-36., https://www.ncbi.nlm.nih.gov/pubmed/30306584

744. Lim, M. C., Lee, H. S., Seo, S. S., Kim, M. S., Kim, J. Y., Zo, J. I., et.al. Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery, Gynecol Oncol, 2010. 116: p. 478-82., https://www.ncbi.nlm.nih.gov/pubmed/19889448

745. Fleisch, M. C., Pantke, P., Beckmann, M. W., Schnuerch, H. G., Ackermann, R., Grimm, M. O., et.al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers, J Surg Oncol, 2007. 95: p. 476-84., https://www.ncbi.nlm.nih.gov/pubmed/17192947

746. Kim, J. S., Kim, S. Y., Kim, Ki, Cho, M. J., Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix, Int J Radiat Oncol Biol Phys, 2003. 55: p. 1247-53., https://www.ncbi.nlm.nih.gov/pubmed/12654434

747. Hirte, H. W., Strychowsky, J. E., Oliver, T., Fung-Kee-Fung, M., Elit, L., Oza, A. M., Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review (Structured abstract), International Journal of Gynecological Cancer, 2007. 17: p. 1194-1204., https://www.ncbi.nlm.nih.gov/pubmed/17540006

748. Tzioras, S., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P., Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis (Structured abstract), Cancer Treatment Reviews, 2007. 33: p. 24-38., https://www.ncbi.nlm.nih.gov/pubmed/17112673

749. Tewari, K. S., Monk, B. J., Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group, Semin Oncol, 2009. 36: p. 170-80., https://www.ncbi.nlm.nih.gov/pubmed/19332251

750. Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F., Barni, S., A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer, Gynecol Oncol, 2014. 133(1): p. 117-23., https://www.ncbi.nlm.nih.gov/pubmed/24486604

751. Tsubamoto, H., Inoue, K., Ukita, Y., Ito, Y., Kanazawa, R., Long-term remission after multiple bone metastases following cervical cancer: A case report, Gynecol Oncol Case Rep, 2013. 5: p. 22-4., https://www.ncbi.nlm.nih.gov/pubmed/24371687

752. Scatchard, K., Forrest, J. L., Flubacher, M., Cornes, P., Williams, C., Chemotherapy for metastatic and recurrent cervical cancer, Cochrane Database Syst Rev, 2012. 10: p. CD006469., https://www.ncbi.nlm.nih.gov/pubmed/23076924

753. Tewari, K. S., Sill, M. W., Long, H. J., 3rd, Penson, R. T., Huang, H., Ramondetta, L. M., et.al. Improved survival with bevacizumab in advanced cervical cancer, N Engl J Med, 2014. 370(8): p. 734-43., https://www.ncbi.nlm.nih.gov/pubmed/24552320

754. Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., et.al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study, Gynecol Oncol, 2012. 127(3): p. 451-5., https://www.ncbi.nlm.nih.gov/pubmed/22986144

755. Muggia, F. M., Blessing, J. A., Method, M., Miller, D. S., Johnson, G. A., Lee, R. B., et.al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, Gynecol Oncol, 2004. 92(2): p. 639-43., https://www.ncbi.nlm.nih.gov/pubmed/14766259

756. Sutton, G. P., Blessing, J. A., DeMars, L. R., Moore, D., Burke, T. W., Grendys, E. C., A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium, Gynecol Oncol, 1996. 63(1): p. 25-7., https://www.ncbi.nlm.nih.gov/pubmed/8898163

757. Bookman, M. A., Blessing, J. A., Hanjani, P., Herzog, T. J., Andersen, W. A., Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group, Gynecol Oncol, 2000. 77(3): p. 446-9., https://www.ncbi.nlm.nih.gov/pubmed/10831357

758. Lorusso, D., Ferrandina, G., Pignata, S., Ludovisi, M., Vigano, R., Scalone, S., et.al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group, Ann Oncol, 2010. 21(1): p. 61-6., https://www.ncbi.nlm.nih.gov/pubmed/19605508

759. Verschraegen, C. F., Levy, T., Kudelka, A. P., Llerena, E., Ende, K., Freedman, R. S., et.al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix, J Clin Oncol, 1997. 15(2): p. 625-31., https://www.ncbi.nlm.nih.gov/pubmed/9053486

760. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6: p. CD011129., https://www.ncbi.nlm.nih.gov/pubmed/28603881

761. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. [Integration of palliative care into intensive care : Systematic review], Anaesthesist, 2017. 66(9): p. 660-666., https://www.ncbi.nlm.nih.gov/pubmed/28589374

762. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., https://www.ncbi.nlm.nih.gov/pubmed/24621947

763. Vinh-Hung, V., Bourgain, C., Vlastos, G., Cserni, G., De Ridder, M., Storme, G., et.al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study, BMC Cancer, 2007. 7: p. 164., https://www.ncbi.nlm.nih.gov/pubmed/17718897

764. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., https://www.ncbi.nlm.nih.gov/pubmed/26231807

765. Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925., https://www.ncbi.nlm.nih.gov/pubmed/28676557

766. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826

767. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://www.ncbi.nlm.nih.gov/pubmed/26464077

768. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/27185614

769. Radbruch, L., Payne, S., White Paper on standards and norms for hospice and palliative care in Europe: part 2, European Journal of Palliative Care, 2010. 17(1): p. 22-33.

770. WHO, Palliative care, Geneva, 2007. p. 62.

771. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7., https://www.ncbi.nlm.nih.gov/pubmed/22312101

772. European Association for Palliative Care (EAPC), Lukas Radbruch, Sheila Payne, Board of Directors of the EAPC outline, White Paper on standards and norms for hospice and palliative care in Europe: part 1, European Journal of Palliative Care, 2009.

773. network, National comprehensive cancer, Palliative Care 2.2012, Clinical practical guidelines in oncology, 2012., www.nccn.org

774. Project, National Consensus, National Consensus Project for Quality Palliative Care, Clinical Practice Guidelines for Quality Palliative Care Second Edition., 2009., http://www.nationalconsensusproject.org

775. Improvement, Institute for Clinical Systems, Health care guidelines: palliative care- 3d edition, 2009.

776. Douglas, C., Murtagh, F. E., Chambers, E. J., Howse, M., Ellershaw, J., Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group, Palliat Med, 2009. 23(2): p. 103-10., https://www.ncbi.nlm.nih.gov/pubmed/19273566

777. Committee, Ontario Guidelines Advisory, Palliative Care: Recognizing Eligible Patients and Starting the Discussion, 2008., http://www.icsi.org/guidelines_and_more/guidelines__order_sets___protocols/, other_health_care_conditions/palliative_care/palliative_care_11875.html

778. John P. Griffin, MD, FCCP; Kathryn A. Koch, MD, FCCP; Judith E. Nelson, MD, JD, FCCP; and Mary E. Cooley, RN, PhD, Palliative Care Consultation, Quality-of-Life Measurements, and Bereavement for End-of-Life Care in Patients With Lung Cancer ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)American College of Chest Physicians, 2007.

779. Organization, World Health, Palliative Care; Cancer control : knowledge into action : WHO guide for effective programmes ; module 5, 2007.

780. Hermanek, P., Hutter, R. V., Sobin, L. H., Wittekind, C., International Union Against Cancer. Classification of isolated tumor cells and micrometastasis, Cancer, 1999. 86: p. 2668-73., https://www.ncbi.nlm.nih.gov/pubmed/10594862

781. Committee, Ontario Guidelines Advisory, Palliative Care: Improving Palliative Care Planning for Identified Patients, 2007., http://www.icsi.org/guidelines_and_more/guidelines__order_sets___protocols/, other_health_care_conditions/palliative_care/palliative_care_11875.html

782. (NICE), National Institutie for Clinical Excellence, Improving Supportive and Palliative Care for Adults with Cancer, 2004., www.nice.org

783. NIH State-of-the-Science Conference Statement on improving end-of-life care, NIH Consens State Sci Statements, 2004. 21: p. 1-26., https://www.ncbi.nlm.nih.gov/pubmed/17308546

784. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29(6): p. 755-60., https://www.ncbi.nlm.nih.gov/pubmed/21263086

785. Excellence, National Institute for Clinical, Guidance on Cancer Services; Improving Supportive and Palliative Care for Adults with Cancer; The manual, 2004., www.nice.org.uk

786. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung; AWMF-Registernummer: 128/001-OL Januar 2020:, https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/LL_Palliativmedizin_2.1_Langversion.pdf

787. Dudgeon, D., King, S., Howell, D., Green, E., Gilbert, J., Hughes, E., et.al. Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening, Psychooncology, 2012. 21(4): p. 357-64., https://www.ncbi.nlm.nih.gov/pubmed/21308858

788. Carlson, L. E., Waller, A., Groff, S. L., Zhong, L., Bultz, B. D., Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage, Br J Cancer, 2012. 107(4): p. 617-25., https://www.ncbi.nlm.nih.gov/pubmed/22828610

789. Lindenfeld, J., Albert, N. M., Boehmer, J. P., Collins, S. P., Ezekowitz, J. A., Givertz, M. M., et.al. HFSA 2010 Comprehensive Heart Failure Practice Guideline, J Card Fail, 2010. 16: p. e1-194., https://www.ncbi.nlm.nih.gov/pubmed/20610207

790. Gaertner, J., Frechen, S., Sladek, M., Ostgathe, C., Voltz, R., Palliative care consultation service and palliative care unit: why do we need both?, Oncologist, 2012. 17(3): p. 428-35., https://www.ncbi.nlm.nih.gov/pubmed/22357732

791. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363(8): p. 733-42., https://www.ncbi.nlm.nih.gov/pubmed/20818875

792. Bruera, E., Hui, D., Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care, J Clin Oncol, 2010. 28(25): p. 4013-7., https://www.ncbi.nlm.nih.gov/pubmed/20660825

793. Bruera, E., Yennurajalingam, S., Palliative care in advanced cancer patients: how and when?, Oncologist, 2012. 17(2): p. 267-73., https://www.ncbi.nlm.nih.gov/pubmed/22252934

794. Levy, M. H., Back, A., Benedetti, C., Billings, J. A., Block, S., Boston, B., et.al. NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr Canc Netw, 2009. 7(4): p. 436-73., https://www.ncbi.nlm.nih.gov/pubmed/19406043

795. Mota, F., Microinvasive squamous carcinoma of the cervix: treatment modalities, Acta Obstet Gynecol Scand, 2003. 82: p. 505-9., https://www.ncbi.nlm.nih.gov/pubmed/12780420

796. Gaertner, J., Wuerstlein, R., Klein, U., Scheicht, D., Frechen, S., Wolf, J., et.al. Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project, Breast Care (Basel), 2011. 6(3): p. 215-220., https://www.ncbi.nlm.nih.gov/pubmed/21779227

797. Leitlinie Lymphödem der Sektion Pflege der DGP 2014, https://www.dgpalliativmedizin.de/images/stories/pdf/Leitlinie_Lymphödem_end.pdf

798. Goncalves, C. V., Duarte, G., Costa, J. S., Marcolin, A. C., Bianchi, M. S., Dias, D., et.al. Diagnosis and treatment of cervical cancer during pregnancy, Sao Paulo Med J, 2009. 127: p. 359-65., https://www.ncbi.nlm.nih.gov/pubmed/20512291

799. Ridner, S. H., Dietrich, M. S., Development and validation of the Lymphedema Symptom and Intensity Survey-Arm, Support Care Cancer, 2015. 23(10): p. 3103-12., https://www.ncbi.nlm.nih.gov/pubmed/25752884

800. Pottharst, A., Steckkönig, A., Aulitzky, W., Subkutane Drainage zur Behandlung des malignen Lymphödems in der palliativen Situation nach Versagen der komplexen physikalischen Entstauungstherapie, Zeitschrift für Palliativmedizin, 2009. 10(01): p. 51-54., https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0028-1090170

801. S2k_Fertilitätserhalt bei onkologischen Erkrankungen (AWMF-Registernummer 015/082; Version 1.0; September 2017), https://www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12.pdf

802. Plante, M., Renaud, M. C., Francois, H., Roy, M., Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature, Gynecol Oncol, 2004. 94(3): p. 614-23., https://www.ncbi.nlm.nih.gov/pubmed/15350349

803. Einstein, M. H., Park, K. J., Sonoda, Y., Carter, J., Chi, D. S., Barakat, R. R., et.al. Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes, Gynecol Oncol, 2009. 112(1): p. 73-7., https://www.ncbi.nlm.nih.gov/pubmed/18973933

804. Wright, J. D., Grigsby, P. W., Brooks, R., Powell, M. A., Gibb, R. K., Gao, F., et.al. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy, Cancer, 2007. 110(6): p. 1281-6., https://www.ncbi.nlm.nih.gov/pubmed/17654664

805. Selo-Ojeme, D. O., Ind, T., Shepherd, J. H., Isthmic stenosis following radical trachelectomy, J Obstet Gynaecol, 2002. 22(3): p. 327-8., https://www.ncbi.nlm.nih.gov/pubmed/12521522

806. Covens, A., Rosen, B., Murphy, J., Laframboise, S., DePetrillo, A. D., Lickrish, G., et.al. How important is removal of the parametrium at surgery for carcinoma of the cervix?, Gynecol Oncol, 2002. 84(1): p. 145-9., https://www.ncbi.nlm.nih.gov/pubmed/11748991

807. Jolley, J. A., Battista, L., Wing, D. A., Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature, Am J Perinatol, 2007. 24: p. 531-9., https://www.ncbi.nlm.nih.gov/pubmed/17899494

808. Cibula, D., Potter, R., Planchamp, F., Avall-Lundqvist, E., Fischerova, D., Haie-Meder, C., et.al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer, Virchows Arch, 2018. 472(6): p. 919-936., https://www.ncbi.nlm.nih.gov/pubmed/29725757

809. Zhang, Q., Li, W., Kanis, M. J., Qi, G., Li, M., Yang, X., et.al. Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis, Oncotarget, 2017. 8(28): p. 46580-46592., https://www.ncbi.nlm.nih.gov/pubmed/28418849

810. Shim, S. H., Lim, M. C., Kim, H. J., Lee, M., Nam, E. J., Lee, J. Y., et.al. Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation, PLoS One, 2018. 13(1): p. e0189847., https://www.ncbi.nlm.nih.gov/pubmed/29385139

811. Ramirez, P. T., Pareja, R., Rendon, G. J., Millan, C., Frumovitz, M., Schmeler, K. M., Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?, Gynecol Oncol, 2014. 132(1): p. 254-9., https://www.ncbi.nlm.nih.gov/pubmed/24041877

812. Speiser, Dorothee, Köhler, Christhardt, Schneider, Achim, Mangler, Mandy, Radikale vaginale Trachelektomie, Dtsch Arztebl International, 2013. 110(17): p. 289-295., http://www.aerzteblatt.de/int/article.asp?id=137444

813. Bentivegna, E., Maulard, A., Pautier, P., Chargari, C., Gouy, S., Morice, P., Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature, Fertil Steril, 2016. 106(5): p. 1195-1211 e5., https://www.ncbi.nlm.nih.gov/pubmed/27430207

814. Pareja, R., Rendon, G. J., Vasquez, M., Echeverri, L., Sanz-Lomana, C. M., Ramirez, P. T., Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2cm or larger: A literature review and analysis of oncological and obstetrical outcomes, Gynecol Oncol, 2015. 137(3): p. 574-80., https://www.ncbi.nlm.nih.gov/pubmed/25827293

815. Wallace, W. H., Thomson, A. B., Kelsey, T. W., The radiosensitivity of the human oocyte, Hum Reprod, 2003. 18(1): p. 117-21., https://www.ncbi.nlm.nih.gov/pubmed/12525451

816. Kurt, M., Uncu, G., Cetintas, S. K., Kucuk, N., Guler, S., Ozkan, L., Successful spontaneous pregnancy in a patient with rectal carcinoma treated with pelvic radiotherapy and concurrent chemotherapy: the unique role of laparoscopic lateral ovary transposition, Eur J Gynaecol Oncol, 2007. 28(5): p. 408-10., https://www.ncbi.nlm.nih.gov/pubmed/17966224

817. Lawrenz, B., Jauckus, J., Kupka, M., Strowitzki, T., von Wolff, M., Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases, Fertil Steril, 2010. 94(7): p. 2871-3., https://www.ncbi.nlm.nih.gov/pubmed/20678763

818. Irtan, S., Orbach, D., Helfre, S., Sarnacki, S., Ovarian transposition in prepubescent and adolescent girls with cancer, Lancet Oncol, 2013. 14(13): p. e601-8., https://www.ncbi.nlm.nih.gov/pubmed/24275133

819. Mossa, B., Schimberni, M., Di Benedetto, L., Mossa, S., Ovarian transposition in young women and fertility sparing, Eur Rev Med Pharmacol Sci, 2015. 19(18): p. 3418-25., https://www.ncbi.nlm.nih.gov/pubmed/26439037

820. Kim, J., Turan, V., Oktay, K., Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer, J Clin Endocrinol Metab, 2016. 101(4): p. 1364-71., https://www.ncbi.nlm.nih.gov/pubmed/26751194

821. Salih, S. M., Albayrak, S., Seo, S., Stewart, S. L., Bradley, K., Kushner, D. M., Diminished Utilization of in Vitro Fertilization Following Ovarian Transposition in Cervical Cancer Patients, J Reprod Med, 2015. 60(7-8): p. 345-53., https://www.ncbi.nlm.nih.gov/pubmed/26380495

822. Teh, W. T., Stern, C., Chander, S., Hickey, M., The impact of uterine radiation on subsequent fertility and pregnancy outcomes, Biomed Res Int, 2014. 2014: p. 482968., https://www.ncbi.nlm.nih.gov/pubmed/25165706

823. Tummers, P., Goker, M., Dahm-Kahler, P., Brannstrom, M., Tullius, S. G., Rogiers, X., et.al. Meeting Report: First State-of-the-Art Meeting on Uterus Transplantation, Transplantation, 2019. 103(3): p. 455-458., https://www.ncbi.nlm.nih.gov/pubmed/30747845

824. Brannstrom, M., Dahm-Kahler, P., Uterus transplantation and fertility preservation, Best Pract Res Clin Obstet Gynaecol, 2019. 55: p. 109-116., https://www.ncbi.nlm.nih.gov/pubmed/30711374

825. Brannstrom, M., Johannesson, L., Dahm-Kahler, P., Enskog, A., Molne, J., Kvarnstrom, N., et.al. First clinical uterus transplantation trial: a six-month report, Fertil Steril, 2014. 101(5): p. 1228-36., https://www.ncbi.nlm.nih.gov/pubmed/24582522

826. Piselli, P., Verdirosi, D., Cimaglia, C., Busnach, G., Fratino, L., Ettorre, G. M., et.al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors, Best Pract Res Clin Obstet Gynaecol, 2014. 28(8): p. 1251-65., https://www.ncbi.nlm.nih.gov/pubmed/25209964

827. Alvarez, R. M., Ramanathan, P., Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response, Hum Reprod, 2018. 33(11): p. 2051-2059., https://www.ncbi.nlm.nih.gov/pubmed/27370358

828. Jensen, A. K., Macklon, K. T., Fedder, J., Ernst, E., Humaidan, P., Andersen, C. Y., 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children, J Assist Reprod Genet, 2017. 34(3): p. 325-336., https://www.ncbi.nlm.nih.gov/pubmed/28028773

829. Pacheco, F., Oktay, K., Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis, Reprod Sci, 2017. 24(8): p. 1111-1120., https://www.ncbi.nlm.nih.gov/pubmed/28701069

830. Donnez, J., Dolmans, M. M., Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice, J Assist Reprod Genet, 2015. 32(8): p. 1167-70., https://www.ncbi.nlm.nih.gov/pubmed/26210678

831. Van der Ven, H., Liebenthron, J., Beckmann, M., Toth, B., Korell, M., Krussel, J., et.al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates, Hum Reprod, 2016. 31(9): p. 2031-41., https://www.ncbi.nlm.nih.gov/pubmed/27378768

832. Dittrich, R., Hackl, J., Lotz, L., Hoffmann, I., Beckmann, M. W., Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center, Fertil Steril, 2015. 103(2): p. 462-8., https://www.ncbi.nlm.nih.gov/pubmed/25487750

833. Cordeiro, C. N., Gemignani, M. L., Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety, Obstet Gynecol Surv, 2017. 72(3): p. 184-193., https://www.ncbi.nlm.nih.gov/pubmed/28304416

834. De Vincenzo, R., Tortorella, L., Ricci, C., Cavaliere, A. F., Zannoni, G. F., Cefalo, M. G., et.al. Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome, Gynecol Oncol, 2018. 150(3): p. 398-405., https://www.ncbi.nlm.nih.gov/pubmed/30126588

835. Goncalves, C. V., Duarte, G., Costa, J. S., Marcolin, A. C., Bianchi, M. S., Dias, D., et.al. Diagnosis and treatment of cervical cancer during pregnancy, Sao Paulo Med J, 2009. 127(6): p. 359-65., https://www.ncbi.nlm.nih.gov/pubmed/20512291

836. Fader, A. N., Alward, E. K., Niederhauser, A., Chirico, C., Lesnock, J. L., Zwiesler, D. J., et.al. Cervical dysplasia in pregnancy: a multi-institutional evaluation, Am J Obstet Gynecol, 2010. 203(2): p. 113 e1-6., https://www.ncbi.nlm.nih.gov/pubmed/20522409

837. Morice, P., Uzan, C., Gouy, S., Verschraegen, C., Haie-Meder, C., Gynaecological cancers in pregnancy, Lancet, 2012. 379(9815): p. 558-69., https://www.ncbi.nlm.nih.gov/pubmed/22325661

838. Wright, T. C., Jr., Massad, L. S., Dunton, C. J., Spitzer, M., Wilkinson, E. J., Solomon, D., et.al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ, Am J Obstet Gynecol, 2007. 197(4): p. 340-5., https://www.ncbi.nlm.nih.gov/pubmed/17904956

839. Landoni, F., Maneo, A., Colombo, A., Placa, F., Milani, R., Perego, P., et.al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer, Lancet, 1997. 350: p. 535-40., https://www.ncbi.nlm.nih.gov/pubmed/9284774

840. Han, S. N., Mhallem Gziri, M., Van Calsteren, K., Amant, F., Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies, Ther Adv Med Oncol, 2013. 5(4): p. 211-9., https://www.ncbi.nlm.nih.gov/pubmed/23858330

841. Balleyguier, C., Fournet, C., Ben Hassen, W., Zareski, E., Morice, P., Haie-Meder, C., et.al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging, Clin Imaging, 2013. 37(1): p. 70-6., https://www.ncbi.nlm.nih.gov/pubmed/23206610

842. Boyd SC, Look KY., Prognostic factors for carcinoma of the cervical stump and cervical carcinoma associated with pregnancy., Cme J Gynecol Oncol, 2001. 6: p. 347-56.

843. Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Van Calster, B., et.al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy, Int J Gynecol Cancer, 2019., https://www.ncbi.nlm.nih.gov/pubmed/30898935

844. Germann, N., Haie-Meder, C., Morice, P., Lhomme, C., Duvillard, P., Hacene, K., et.al. Management and clinical outcomes of pregnant patients with invasive cervical cancer, Ann Oncol, 2005. 16(3): p. 397-402., https://www.ncbi.nlm.nih.gov/pubmed/15668263

845. Sorosky, J. I., Squatrito, R., Ndubisi, B. U., Anderson, B., Podczaski, E. S., Mayr, N., et.al. Stage I squamous cell cervical carcinoma in pregnancy: planned delay in therapy awaiting fetal maturity, Gynecol Oncol, 1995. 59(2): p. 207-10., https://www.ncbi.nlm.nih.gov/pubmed/7590474

846. Fukushima, K., Ogawa, S., Tsukimori, K., Kobayashi, H., Wake, N., Can we diagnose invasive cervical cancer during pregnancy as precise as in nonpregnant women?: maternal and perinatal outcome in pregnancies complicated with cervical cancers, Int J Gynecol Cancer, 2009. 19(8): p. 1439-45., https://www.ncbi.nlm.nih.gov/pubmed/20009904

847. Marnitz, S., Kohler, C., Oppelt, P., Schmittel, A., Favero, G., Hasenbein, K., et.al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients, Oncology, 2010. 79(1-2): p. 72-7., https://www.ncbi.nlm.nih.gov/pubmed/21071993

848. Drolet, M., Benard, E., Boily, M. C., Ali, H., Baandrup, L., Bauer, H., et.al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis, Lancet Infect Dis, 2015. 15(5): p. 565-80., https://www.ncbi.nlm.nih.gov/pubmed/25744474

849. Morice, P., Narducci, F., Mathevet, P., Marret, H., Darai, E., Querleu, D., et.al. French recommendations on the management of invasive cervical cancer during pregnancy, Int J Gynecol Cancer, 2009. 19(9): p. 1638-41., https://www.ncbi.nlm.nih.gov/pubmed/19955951

850. Cardonick, E., Usmani, A., Ghaffar, S., Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry, Am J Clin Oncol, 2010. 33(3): p. 221-8., https://www.ncbi.nlm.nih.gov/pubmed/19745695

851. Capriglione, S., Manzano, A., Gulino, F. A., Lopez, S., Management of gynecological cancer in pregnant patients, Minerva Ginecol, 2019. 71(2): p. 133-145., https://www.ncbi.nlm.nih.gov/pubmed/30318875

852. de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., et.al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients, Lancet Oncol, 2018. 19(3): p. 337-346., https://www.ncbi.nlm.nih.gov/pubmed/29395867

853. Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., et.al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting, Int J Gynecol Cancer, 2014. 24(3): p. 394-403., https://www.ncbi.nlm.nih.gov/pubmed/24445819

854. Vercellino, G. F., Koehler, C., Erdemoglu, E., Mangler, M., Lanowska, M., Malak, A. H., et.al. Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome, Int J Gynecol Cancer, 2014. 24(2): p. 364-71., https://www.ncbi.nlm.nih.gov/pubmed/24424374

855. Esposito, S., Tenconi, R., Preti, V., Groppali, E., Principi, N., Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes, Medicine (Baltimore), 2016. 95(38): p. e4899., https://www.ncbi.nlm.nih.gov/pubmed/27661036

856. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Bartsch, R., Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis, Obstet Gynecol, 2013. 121(2 Pt 1): p. 337-343., https://www.ncbi.nlm.nih.gov/pubmed/23344284

857. Kohler, C., Oppelt, P., Favero, G., Morgenstern, B., Runnebaum, I., Tsunoda, A., et.al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy, Am J Obstet Gynecol, 2015. 213(2): p. 206 e1-5., https://www.ncbi.nlm.nih.gov/pubmed/25731691

858. Cardonick, E. H., Gringlas, M. B., Hunter, K., Greenspan, J., Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls, Am J Obstet Gynecol, 2015. 212(5): p. 658 e1-8., https://www.ncbi.nlm.nih.gov/pubmed/25434835

859. Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., et.al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy, N Engl J Med, 2015. 373(19): p. 1824-34., https://www.ncbi.nlm.nih.gov/pubmed/26415085

860. Vandenbroucke, T., Verheecke, M., Fumagalli, M., Lok, C., Amant, F., Effects of cancer treatment during pregnancy on fetal and child development, Lancet Child Adolesc Health, 2017. 1(4): p. 302-310., https://www.ncbi.nlm.nih.gov/pubmed/30169185

861. Hopkins, M. P., Morley, G. W., The prognosis and management of cervical cancer associated with pregnancy, Obstet Gynecol, 1992. 80(1): p. 9-13., https://www.ncbi.nlm.nih.gov/pubmed/1318532

862. Smith, A. L., Frumovitz, M., Schmeler, K. M., dos Reis, R., Nick, A. M., Coleman, R. L., et.al. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?, Gynecol Oncol, 2010. 119: p. 183-6., https://www.ncbi.nlm.nih.gov/pubmed/20708227

863. Hsu, W. L., Shueng, P. W., Jen, Y. M., Wu, C. J., Hwang, J. M., Chang, L. P., et.al. Long-term treatment results of invasive cervical cancer patients undergoing inadvertent hysterectomy followed by salvage radiotherapy, Int J Radiat Oncol Biol Phys, 2004. 59: p. 521-7., https://www.ncbi.nlm.nih.gov/pubmed/15145172

864. Park, J. Y., Kim, D. Y., Kim, J. H., Kim, Y. M., Kim, Y. T., Nam, J. H., Management of occult invasive cervical cancer found after simple hysterectomy, Ann Oncol, 2010. 21: p. 994-1000., https://www.ncbi.nlm.nih.gov/pubmed/19858083

865. Munstedt, K., Johnson, P., von Georgi, R., Vahrson, H., Tinneberg, H. R., Consequences of inadvertent, suboptimal primary surgery in carcinoma of the uterine cervix, Gynecol Oncol, 2004. 94: p. 515-20., https://www.ncbi.nlm.nih.gov/pubmed/15297197

866. Tran, A. Q., Sullivan, S. A., Gehrig, P. A., Soper, J. T., Boggess, J. F., Kim, K. H., Robotic Radical Parametrectomy With Upper Vaginectomy and Pelvic Lymphadenectomy in Patients With Occult Cervical Carcinoma After Extrafascial Hysterectomy, J Minim Invasive Gynecol, 2017. 24(5): p. 757-763., https://www.ncbi.nlm.nih.gov/pubmed/28254677

867. Tian, W. J., Zhang, M. Q., Shui, R. H., Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix, Oncol Lett, 2012. 3: p. 125-130., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362381/

868. Wittekind, C, TNM Klassifikation maligner Tumoren - Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019Wiley-VCH, Weinheim, 2020.